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ABSTRACT 
 
KATHLEEN E. DAVIS 
DIET, ADIPOSITY, AND ADVANCED GLYCATION END PRODUCTS 
MAY 2013 
The purpose of this dissertation is to explore factors which may affect the serum soluble 
receptor for advanced glycation end products (sRAGE) and to determine whether macronutrient 
diet composition impacts inflammation and levels of serum n-epsilon-carboxymethyl-lysine 
(CML), a measure of advanced glycation endproducts. 
In study I, we tested the hypothesis that sRAGE is correlated to adiposity in a young, 
ethnically-diverse population. Seventy-two healthy adult participants were recruited for the study 
and anthropometric measurements were collected. Sera from all participants were analyzed for 
sRAGE and CML. In addition, in a subgroup of participants (n=34), serum levels of adiponectin, 
total cholesterol, high density lipoprotein, and triacylglycerol were determined. sRAGE was 
inversely correlated with weight (-0.364; p=0.002), waist circumference (-0.334; p=0.004), and 
BMI (-0.364; p= 0.002). High molecular adiponectin was positively correlated to sRAGE (0.416; 
p=0.02). This is the first time these associations have been found in a young, ethnically-diverse 
population.  
In study II, we hypothesized that dietary fat content influenced serum sRAGE, CML, and 
markers of inflammation. Eighteen subjects participated in a feeding study of two diets, one high 
in fat and the other low in fat, both high in dietary AGEs. Participants were provided breakfast, 
lunch, dinner and snacks for a single day. Baseline and postprandial sera were analyzed for CML, 
vi 
sRAGE, adiponectin and C-reactive protein (CRP). Compared to high-fat diet, low-fat diet 
decreased serum CML. 
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CHAPTER I 
INTRODUCTION 
   Advanced glycation end products (AGE) are a diverse group of compounds formed 
when glucose or other reducing sugars react with amino acids, nucleotide bases or fatty acids, 
forming glycosylated molecules. Some of these products include pentosidine, 
carboyxmethyllysine (CML), hydroimidazolone, furosine, and glucosepane (Semba 2010). Those 
AGEs formed from reactions with polyunsaturated fatty acids are known as ALEs (advanced 
lipoperoxidation end products) (Kalousova 2005; Uribarri 2005; Semba 2010).  AGEs are 
produced when the Amadori product of the interaction between a reducing sugar and the amino 
acid attached to a protein, lipid or nucleic acid is further modified by dehydration, oxidation, 
rearrangement or other reactions, leading to the formation of cross linked derivatives of sugar and 
other molecules (Barlovic 2011).  
 Current research suggests that AGEs have both endogenous and exogenous (dietary) 
origins and may increase oxidative and carbonyl stress by interacting with the receptor for AGE 
(RAGE), decreasing cardiovascular endothelial dysfunction and exacerbating the consequences of 
diabetes. The soluble receptor for AGE (sRAGE) is thought to act as a decoy receptor, aiding the 
body in ridding it of AGEs.  
Endogenous AGE formation is up-regulated in conditions of metabolic stress such as 
sepsis and insulin resistance and in disease states such as diabetes and chronic kidney disease. 
Endogenous AGE production generally occurs slowly; however, conditions such as those listed 
above increase oxidative stress and thus may increase formation of AGE (Barlovic 2011). 
Hyperglycemia may lead to up-regulation of pathways other than glycolysis including the polyol 
2 
pathway, which increases AGE production. Activation of protein kinase C could also stimulate 
the hexosamine pathway, increasing endogenous AGE. Furthermore, an increase in reactive 
dicarbonyls and reduced detoxification by the glyoxalase system is thought to lead to a state of 
carbonyl stress, which may increase endogenous AGE (Barlovic 2011). 
The body has some capacity to degrade AGEs. Degradative enzymes including 
glyoxalase I and II help to degrade and detoxify AGE along with aldose reductase and carbonyl 
reductase, which reduce AGEs, decreasing their destructive potential. Circulating proteins such as 
lysozyme, defensins and lactoferrin may also bind AGEs in circulation, preventing them from 
binding elsewhere within the cells (Vlassara 2008). However, it appears that degradation is not 
always rapid enough to keep up with production. In cases of hyperglycemia or severe oxidative 
stress, degradation may not keep up with production. In fact, in kidney disease the body appears 
to decrease its capacity to degrade and excrete AGE to sufficient levels (Koschinsky 1997). 
There are two types of cell surface AGE receptors (RAGE/AGER), one which binds 
AGE and initiates cell activation and another which binds, internalizes and degrades AGE. The 
membrane bound RAGE receptor for AGE is thought to initiate oxidative stress whereas the 
AGERs 1, 3, and CD35 receptor help to mediate degradation of AGE (Vlassara 2008). Damage 
caused by AGEs is caused by activation of nuclear factor kappa beta (NF-ĸβ) which leads to up-
regulation of genes for cytokines, growth factors and cell adhesion molecules (Kalousova 2005). 
In addition sRAGE, a truncated variant of the parent receptor, may play an anti-inflammatory role 
by binding to AGE, making it unavailable for RAGE. 
Because AGEs are essentially glycated molecules, one might expect that foods rich in 
carbohydrates would be important dietary sources. This is generally not the case. Exogenous 
AGE consumption typically increases in high fat diets and when high temperature cooking 
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methods such as deep-frying, broiling, roasting and grilling are used. High protein products 
cooked in these ways tend to be particularly high in AGEs (Semba 2010).  
Whether endogenous AGE is primarily significant or whether exogenous AGE may 
contribute significantly to deleterious health effects is a topic under current research. Exogenous 
AGE or dietary AGEs were once considered insignificant; however, this viewpoint is changing. 
Early research showed that only 10% of dietary AGE is absorbed (Sgarbieri 1973). Another study 
evaluating absorption in 43 diabetic subjects and five non-diabetic subjects was completed in 
1997 with similar results: about 10% of dietary AGE was found to be absorbed with just 30% 
being excreted in persons with normal kidney function and as little as five percent excreted in 
those with impaired kidney function (Koschinsky 1997). 
It has been reported that Western diet is high in AGE, but studies which clearly document 
a controlled, repeatable method of determining AGE in foods and capturing AGE concentrations 
in a variety of foods and diets are lacking. In most studies, CML has been the AGE used to 
determine AGE content of foods (Semba 2010). Many later studies have used the tables 
developed by one particular group to calculate AGE in their intervention studies rather than 
measuring AGE in the test foods (Goldberg 2004). The Goldberg study took a variety of foods 
purchased from convenience stores and fast food restaurants and prepared them using standard 
cooking times with variation in cooking methods: boiled, broiled, deep fried, oven fried and 
roasted. All foods were analyzed for AGE using an analysis that quantifies CML using ELISA. 
However, the methods section does not detail whether multiple samples/trials were done in order 
to determine AGE, a possible limitation of the research method. This study found that AGE was 
lowest in carbohydrate foods with the lowest within this group being found in milk, followed by 
vegetables and fruits. Broiled beef, and chicken, oils heated to high levels and roasted nuts were 
4 
among the highest CML foods. Using these charts the researchers analyzed 3 day food records 
from healthy participants and found mean daily AGE intake to be about 16,000 +/- 5000 kU 
AGE. Persons with diabetes were found to have higher AGE intake.   
The impact of dietary AGE on inflammatory markers has been assessed in at least one 
study. Uribarri et. al. correlated calculated dietary AGE content and serum AGE in 90 healthy 
subjects finding increases in CRP with both dietary AGE and serum AGE (Uribarri 2005). In five 
participants taken from this group of 90, short term dietary AGE restriction decreased AGE levels 
by 30-40 percent. Thus it seems likely that dietary AGE may significantly impact AGE levels 
even in healthy individuals despite somewhat low absorption.  Further, restriction of dietary AGE 
may decrease inflammatory markers. 
OPPORTUNITIES IN RESEARCH 
 Adiposity has been linked to increased AGEs in some studies and to decreased sRAGE in 
older, ethnically homogenous populations. How adiposity relates to AGE and sRAGE in a young, 
diverse population has not been described.  
 Another area of research yet to be fully elucidated in the field of AGE/RAGE biology and 
nutrition includes how dietary AGE and other factors may influence disease risk. A more 
thorough review of the literature will help to elucidate these factors.  
 Finally, within the field of AGE/RAGE biology and nutrition knowledge of the interaction 
of dietary AGE and sRAGE is incomplete.  While the literature documents many characteristics 
which may affect sRAGE (BMI, TG, sex, age), it is not well established whether a dietary 
challenge which is high in AGE may modify sRAGE levels. Even the role of dietary AGE in 
determining serum AGE is now in question since the publication of a study by Semba et. al. in 
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early 2012 which found no relationship between dietary records detailing AGE intake and serum 
AGE. 
 It is not clear whether dietary macronutrient composition impacts the effect of a high AGE 
diet. Studies have compared a high AGE low-fat diet to a low AGE low-fat diet; however, no 
study compares high AGE low fat and high AGE high fat diets. Much has been made of the 
importance of low fat diet in lowering risk of cardiovascular disease. However, cooking methods 
recommended for lowering fat intake such as broiling, grilling and roasting tend to increase 
concentrations of advanced glycation end products (AGEs) in foods. Current research suggests 
that AGEs increase oxidative and carbonyl stress, may increase cardiovascular endothelial 
dysfunction, and contribute to cellular damage related to diabetes and chronic kidney disease. In 
addition increased body fat and body weight are associated with higher levels of AGE and 
decreased levels of an important receptor for AGE (sRAGE). Since low fat diet is often 
recommended for weight control in obese and overweight persons, it is important to determine 
whether a low fat diet prepared using these commonly advised cooking methods contributes to 
AGE load and negatively affects inflammatory cytokines thought to be influenced by AGE.  
  Will a low fat diet cooked using these high heat methods have equivalent effects on 
serum AGE and inflammatory cytokines when compared to a high fat diet cooked in these ways? 
Will consumption of a low fat diet using these cooking methods have the same effects on serum 
AGE and sRAGE compared to a high fat diet?   
OBJECTIVES 
There are three parts to this study. The purpose of the first part is to describe the 
relationship among indicators of adiposity, CML, sRAGE, and other metabolic biomarkers in 
young, healthy, ethnically-diverse adults. 
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The purpose of the second part is to summarize and describe the relationship among 
dietary AGE and disease risk in adults.  
The purpose of the third part is to determine the effect of a high AGE challenge meal on 
serum AGE, sRAGE and indicators of inflammation including C-reactive protein (CRP) and high 
molecular weight (HMW) adiponectin in overweight/obese, healthy individuals ages 20-45.  This 
study will also evaluate the effect of both a low-fat high AGE and high-fat high AGE diet on 
these indicators. In addition because recent studies have shown no correlation between dietary 
records detailing AGE dietary content and serum AGE, the study will help elucidate whether 
dietary AGE is important in determining serum AGE. 
CENTRAL HYPOTHESES 
 sRAGE will correlate inversely with indicators of adiposity in young, healthy, ethnically 
diverse adults. 
 sRAGE will increase in response to an AGE bolus. 
 AGE will increase in the serum of participants in response to an AGE bolus and will 
remain elevated the next day. 
 Participants consuming high AGE diets will have increases in serum levels of AGE 
(measured using CML), increased levels of sRAGE and increased levels of CRP.  
 Participants consuming the low-fat high AGE diet will have a reduced response in serum 
AGE (CML), sRAGE and CRP compared to those consuming the high fat high AGE diet. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
ADVANCED GLYCATION END PRODUCTS (AGEs)  
Significance in Physiology 
Advanced glycation end products (AGE) are a diverse group of compounds formed when 
glucose or other reducing sugars react with amino acids, nucleotide bases or fatty acids, forming 
glycosylated products. Some of these products include pentosidine, carboyxmethyllysine (CML), 
furosine, hydroimidazolone and glucosepane (Semba 2010). In order for AGEs to be produced, 
the Maillard browning reaction must first occur. This non-enzymatic reaction takes place when a 
reducing sugar interacts with amino groups attached to proteins, lipids or nucleic acids, producing 
a Schiff base which then forms more stable Amadori products. Up to the point of the creation of 
Amadori products, these reactions are reversible, so AGEs may not result from the initial 
browning reaction.  AGEs are produced when the Amadori products are further modified by 
dehydration, oxidation, rearrangement or other reactions, leading to the formation of cross linked 
derivatives of sugar and other molecules (Barlovic 2011). Two well known Amadori products are 
hemoglobin A1c and fructosamine; however, neither of these are AGEs. 
AGEs have both endogenous and exogenous (dietary) origins and are thought to 
contribute to oxidative stress within the body (Vlassara 2002). Endogenous AGE formation is up-
regulated in conditions of metabolic stress such as sepsis and insulin resistance and in disease 
states such as diabetes and chronic kidney disease. Endogenous AGE production generally occurs 
slowly; however, conditions such as those listed above increase oxidative stress and thus may 
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increase formation of AGEs (Barlovic 2011; Vlassara 2002). Hyperglycemia may lead to up-
regulation of pathways other than glycolysis including the polyol pathway, which increases AGE 
production. Activation of protein kinase C could also stimulate the hexosamine pathway, 
increasing endogenous AGE. Furthermore, an increase in reactive dicarbonyls and reduced 
detoxification by the glyoxalase system is thought to lead to a state of carbonyl stress, which may 
increase endogenous AGE (Barlovic 2011). 
Degradative enzymes including glyoxalase I and II help to degrade and detoxify AGE 
along with aldose reductase and carbonyl reductase,  decreasing their destructive potential. 
Circulating proteins such as lysozyme, defensins and lactoferrin may also bind AGEs in 
circulation, preventing them from binding elsewhere within the cells (Vlassara 2008; Vlassara 
2002). However, it appears that degradation is not always rapid enough to keep up with 
production.  In cases of hyperglycemia or severe oxidative stress, degradation may not keep up 
with production. In kidney disease the body appears to decrease its capacity to degrade and 
excrete AGE to sufficient levels (Koschinsky 1997). 
There are two types of cell surface AGE receptors, one which binds AGE and initiates 
cell activation and another which binds, internalizes and degrades AGE. The RAGE receptor for 
AGE is thought to initiate oxidative stress whereas the AGERs 1, 3, and CD35 receptors help to 
mediate degradation of AGE (Vlassara 2008). Damage caused by AGEs is caused by activation 
of nuclear factor kappa beta (NF-ĸβ) which leads to up-regulation of genes for cytokines, growth 
factors and cell adhesion molecules (Kalousova 2005).  
Dietary AGEs: Current Dietary Data 
Because AGEs are essentially glycated molecules, one might expect that foods rich in 
carbohydrates would be important dietary sources. Instead exogenous AGE consumption 
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typically increases in high fat diets and when high temperature cooking methods such as deep-
frying, broiling, roasting and grilling are used. This is particularly true for high protein products 
(Semba 2010; Uribarri 2010).  In addition, various cooking techniques may inhibit AGE 
production including exposing meats to acidic solutions (marinating) and chemical AGE 
inhibitors (aminoguanidine) (Uribarri, 2010).  
Whether endogenous AGE is primarily significant or whether exogenous AGE may 
contribute significantly to deleterious health effects is a topic under current research. Exogenous 
AGE or dietary AGEs were once considered insignificant; however, this viewpoint is changing. 
Early research showed that 10% of dietary AGE is absorbed (Sgarbieri 1973). Another study 
evaluating absorption in 43 diabetic subjects and five non-diabetic subjects completed in 1997 
resulted in similar findings: about 10% of dietary AGEs were found to be absorbed with just 30% 
being excreted in persons with normal kidney function and as little as five percent excreted in 
those with impaired kidney function (Koschinsky 1997). An in vitro experimental model 
assessing diet derived AGEs’ effects on glutathione (GSH) and GSH peroxidase (GPx), indicators 
of oxidative stress, on human umbilical vein endothelial cells (HUVECs), determined that AGEs 
depleted GSH and increased GPx activity (Cai 2002). Thus, it was concluded that food-derived 
AGEs, prior to absorption at least, do contain carbonyl species that may induce oxidative damage.  
It has been reported that Western diet is high in AGEs. At least two large studies have 
attempted to quantify AGEs in a variety of foods (Goldberg 2004; Uribarri, 2010). These studies 
were performed by the same group using the same method (ELISA with anti-CML antibody). 
Another smaller study by Hull et. al. used HPLC-mass spectrophotometry to determine CML 
concentrations in foods (Hull, 2012). In most studies, CML has been the AGE used to determine 
AGE content of foods (Semba 2010). This is based on earlier studies indicating that CML levels 
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directly correlate with levels of other protein or lipid AGEs (Cai 2008; Brownlee 2001; Requena 
1997). Thus, while information on AGEs in foods is increasing, studies capturing a variety of 
AGE concentrations in a variety of foods and diets are lacking. In addition, methods used to 
determine AGEs in foods vary, and the method used to calculate AGEs in the largest studies 
(Goldberg 2004 and Uribarri 2010) have been criticized for the lack of specificity of the method 
and for using ―units per 100 g‖ rather than a more specific quantification.  
Many recent dietary intervention studies have used the tables developed by one particular 
group to calculate AGE in their test diets rather than measuring AGE in the test foods (Goldberg 
2004). The Goldberg study took a variety of foods purchased from convenience stores and fast 
food restaurants and prepared them using standard cooking times with variation in cooking 
methods: boiled, broiled, deep fried, oven fried and roasted. All foods were analyzed for AGE 
using an analysis that quantifies CML using ELISA. However, the methods section does not 
detail whether multiple samples/trials were performed in order to determine AGE, a possible 
limitation of the research method. Using this method of determining AGE, AGEs were lowest in 
carbohydrate foods with the lowest levels within this group being found in milk, followed by 
vegetables and fruits. Broiled beef, and chicken, oils heated to high levels and roasted nuts were 
among the highest CML foods. Using these charts the researchers analyzed 3 day food records 
from healthy participants and found mean daily AGE intake to be about 16,000 +/- 5000 kU 
AGE. Persons with diabetes were found to have higher AGE intake.  
A follow-up study by the same group repeated this same process but using greater 
variations in cooking techniques: marinating, various temperatures, AGE inhibitors, and made 
new discoveries in this area of research (Uribarri, 2010). According to this research fats have 
higher levels of AGEs per gram, but meats contribute more to dietary AGEs due to larger serving 
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sizes. Beef and cheese were found to have the highest levels of AGEs followed by poultry, pork, 
fish and eggs. These are interesting findings given the fact that red meats have come to be 
synonymous with heart disease in the public mind. In addition, higher fat and aged cheeses were 
found to have more AGEs than lower fat cheeses. Methylglyoxal levels (MG) were also 
quantified in this study and found to correlate well with CML; however, it is clear from reviewing 
the tables in the article that for some foods, concentrations of CML and MG are very different.  
The study by Hull et. al. which used HPLC-MS to determine CML in foods actually 
found that AGEs were highest in cereal and lowest in fruits and vegetables expressed as mg/100 g 
of food. However, CML remained highest for meat products when expressed as mg per average 
serving. (Hull, 2012).  
A brief discussion of several studies which have quantified AGE in foods follows. A 
study of infant formulas purchased in Europe found elevated concentrations of various AGEs 
including CML with 3-8 fold higher concentrations in liquid infant formula compared to cow’s 
milk and 2.5-5 times higher concentration in powdered infant formula compared to standard 
powdered milk (Birlouez-Aragon 2004).  In addition, a study comparing concentration of AGE in 
breast milk and formula fed infants found infant formula to be 70 times higher in CML compared 
to breast milk.  Plasma levels of AGE were also consistently higher AGE in formula fed infants 
compared to breast-fed infants (Sebekova 2008).   
A study of a variety of common foods published in 2009 found levels of CML to vary 
from as low as 0.3 mg/kg of raw milk and 0.35 mg/kg of skim milk to as high as 46.1 mg/kg of 
wholemeal bread crust (compared to just 4.45 mg/kg of bread crumb) (Assar 2009). Commercial 
breakfast cereals, ice cream and barbecue sauces also appear to be sources of AGE (Delgado-
Andrade 2006; Drusch 1999; Chao 2009).  An evaluation of a variety of processing methods for 
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nuts and seeds found that CML production was increased by roasting methods. Thus consumption 
of cooked foods compared to raw foods increases AGE ingestion (Yaacoub 2008).  
Low-fat vegan diets are lower in AGEs (McCarty 2004). However, this may not be a 
benefit of vegan diet. In fact, some research indicates that plasma AGE is actually higher in 
vegans despite their low ingestion of high AGE foods, perhaps due to dietary interaction between 
low taurine ingestion combined with low AGE intake. 
Intermediate products which may or may not form AGEs include methylglyoxl (MG) and 
glyoxal (GO). Concentrations of these compounds have also been evaluated in foods. In one 
study a variety of commonly found soft drinks were analyzed. In general the trend was for 
products containing high fructose corn syrup to be relatively high in MG whereas diet drinks 
were not (Tan 2008). However, a study by Uribarri et. al. which quantified both CML and MG 
found high quantities of MG in diet Coke and low MG in regular Coke with low quantities of 
CML in both diet and regular Coke. For Pepsi, the reverse was true; regular Pepsi had high levels 
of MG whereas some forms of diet Pepsi had low levels of MG, and both had low levels of CML 
(Uribarri 2010).   
In yet another analysis in which soft drinks were evaluated for AGEs using ELISA, AGE 
levels in soft drinks did not correlate with sugar content as long as protein and heat were not 
present. In fact drinks with caramel additives such as Coke Classic or Diet Coke were found to 
contain 8500 and 9500 units/cup compared to 475 units per cup in Sprite, 600 in orange juice and 
around 2000 in coffee and tea. (Koschinsky 1997).  
One problem with these studies is that they vary in the method of quantifying AGE, and 
some quantify CML versus other AGE products. Some use ELISA, others GC and others HPLC. 
Methods of extraction also vary for analyses. Thus, having some standard methods for 
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determining and quantifying AGE might help in creating comparable studies (Ames 2008; 
Delgado-Andrade 2007; Drusch 1999). The techniques used by opposing groups have been 
published and repeated (Hull 2012; Ames 2008; Assar 2009; Uribarri 2010; Goldberg 2004; Cai 
2002; Mitsuhashi 1997), but given different units of measurement and different findings, the data 
remains confusing.  
Potential Negative Consequences of AGE Consumption 
 
Current studies have many limitations, yet some trends appear. Uribarri et. al. correlated 
calculated dietary AGE content and serum AGE in 90 healthy subjects finding increases in CRP 
to be correlated with both dietary AGE and serum AGE (Uribarri 2005). In five participants taken 
from this group of 90, short term dietary AGE restriction decreased AGE levels by 30-40 percent. 
Another study of healthy subjects randomized to a low AGE diet also found reductions in 8-
isoprostanes, vascular cell adhesion protein 1 (VCAM-1) and tumor necrosis factor-α (TNF-α) in 
subjects following the diet (Vlassara, 2009). In studies of mice assigned to high fat high AGE or 
high fat low AGE diets, similar trends were identified, with mice in the high fat high AGE group 
accumulating more visceral fat, the majority of them developing diabetes and having higher body 
weight and serum AGES than the high fat low AGE fed mice or the controls (Sandu 2005).  In 
addition, the high fat high AGE diet fed mice had higher levels of 8-isoprostanes and lower 
adiponectin.  A separate study of 36 diabetic and 18 healthy human subjects randomized to 
standard diet or AGE-restricted diet for 4 months identified significant, positive changes in 
insulin, leptin, 8-isoprostane and NF-KB levels in patients with diabetes but reductions in only 
serum CML and 8 isoprostanes in healthy subjects (Uribarri 2011). Based on animal and human 
data to date, it seems likely that dietary AGE may significantly impact AGE levels even in 
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healthy individuals despite somewhat low absorption. This is not a uniformly accepted finding. 
Controversy remains about the importance of dietary AGE. 
Absorption and Effects of Ingestion of AGE 
 
Several studies have documented impacts of short term AGE feeding on cellular 
processes. One of the earliest studies of AGE diet by Koschinsky et. al. evaluated the effect of a 
single meal containing egg white cooked with or without fructose (with=AGE; without=control) 
in 38 participants with type 2 diabetes. It was this study that first showed that not only did AGE 
increase with dietary consumption but that AGE levels remained elevated in persons with both 
diabetes and severe renal disease for more than 48 hours after ingestion (Koschinsky 1997). This 
provided impetus for research into whether AGEs could be responsible for some of the tissue 
damage which is present in diabetes. 
A Greek group evaluating the effects of exogenous AGE on serum AGE in healthy 
women and women with polycystic ovarian syndrome (PCOS) studied the effects of a single high 
AGE meal on serum AGE in 36 women. The meal consisted of ―overcooked‖ chicken nuggets, 
potato chips, meringue and Coke. They found increases in serum AGE in both normal women 
and women with PCOS (Diamanti-Kandarakis 2006). In this study a competitive AGE ELISA 
developed by the researchers was used to assess serum AGE content. An AGE profile of the test 
meal was not included. In addition, the researchers did not document negative effects of AGE, 
instead simply reporting that dietary AGE increased serum AGE. 
A 2007 study attempted to show that dietary AGE had negative physiological 
consequences. Forty-four stable diabetic participants and 10 healthy participants were given an 
oral AGE challenge beverage containing 1.8 x 10
6
 units of AGE but no carbohydrate or lipid 
(being based primarily on diet Coke). Brachial artery flow mediated dilation (FMD) was then 
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monitored for 72 hours. Maximal arterial dilation after ischemia decreased significantly with no 
changes in glucose or VCAM-1. This decrease in FMD is thought to be indicative of impaired 
endothelial function resulting from the AGE bolus (Uribarri 2007).  
In a 2007 study by the same group, 20 participants with type 2 diabetes were given 
isocaloric diets with identical ingredients but which were prepared using different cooking 
methods in order to obtain high and low AGE test meals followed by measurement of endothelial 
function using FMD and Laser-Doppler flowometry. Each participant was fed the low AGE diet 
on day 4 of the study and the high AGE on day 6 followed by FMD monitoring during each 
phase. Again, FMD was found to decrease significantly more after the high AGE meal (a 
decrease which was1.5 times greater than the low AGE meal change). AGE did not affect 
glucose, triacylglycerol levels or insulin. No significant changes in inflammatory markers were 
found (Negrean 2007). The researchers did find a decrease in leptin after high AGE feeding.  
They also found decreases in adiponectin and increases in VCAM-1 and e-selectin. (Stirban 
2008). Another study by the same group involving 13 persons with type 2 diabetes found that a 
high AGE test meal significantly impaired macrovascular FMD (Stirban 2006).   
In a cross-over study of 11 patients with diabetes fed two weeks of high AGE followed 
by two weeks of low AGE diets with 1 one week washout between, serum AGES were found to 
increase by almost 65% on the high AGE diet and decreased by 30% on the low AGE diet. In a 
six week study of 13 patients with diabetes, C-reactive protein was found to increase on the high 
AGE diet and decrease on the low AGE diet with AGE LDL also decreasing on low AGE diet 
along with VCAM-1 (Vlassara 2002). 
Others have disputed that AGEs are significantly absorbed or transported in the body. A 
2007 review by Ames discusses a smaller body of the existing literature and reports that the data 
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concerning absorption is very spotty (Ames 2007). In one study of CML feeding involving rats, 
26-29% of CML fed was recovered in the urine, 15-22% in the feces, 1.4% in kidney tissue, very 
small amounts in liver tissue, but half of the CML fed was not accounted for. Some have even 
suggested that CML is degraded by colonic microflora, but unpublished data investigating this 
was not very compelling (Ames 2007). Further complicating the picture, a study of hemodialysis 
patients found that serum CML was actually a positive predictor of survival (perhaps indicating 
good nutritional intake). (Schwedler 2002) 
A review article suggests that genetic factors may be more important in determining 
AGEs in the serum than dietary intake. In non-diabetic twins, CML levels were found to be 
determined by genes not influencing blood glucose instead of diet (Ahmed 2005). In addition 
CML levels in serum have been found to correlate with retinopathy but not with nephropathy in 
diabetics (Ahmed 2005).  Others maintain that CML and dietary intake are highly correlated. One 
study by Uribarri, Cai et. al found that consumption of dietary AGEs assessed by 3 day food 
record correlated with circulating CML (r=0.415). (Uribarri, Cai 2007) More recently Semba et. 
al. found no relationship between dietary records and circulating CML (Semba 2012). 
Long-term AGE Ingestion 
 Very little has been studied in relation to the effects of long-term AGE ingestion on 
indicators of metabolic syndrome, kidney disease, and more. A very suggestive animal study was 
done by Cai et. al in 2008. In it 66 aging, male C67BL/6 mice were assigned to one of three diets: 
a 40% calorie deficient diet balanced in mineral and vitamins (CR diet), the same diet with the 
addition of AGE by extended heat exposure (CR-high diet) and an open formula (Reg) diet.  Food 
consumption was monitored daily for four weeks and then after establishing daily intake, pair 
feeding began. Mice were followed for 112 weeks and blood was taken at 16 and 112 weeks of 
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age when sacrifice occurred for those mice who had not already expired. The micronutrient 
composition among the three diets was identical; the only difference was heating. The CR mice 
had a 45% lower consumption of protein and fat-associated dietary AGEs compared to the Reg 
mice due to the energy restriction. However, the CR-high mice consumed 2 times the AGE of the 
calorie restricted mice and 1.8 times greater than the Reg mice. After 56 weeks, the CR-high mice 
had higher body weight than the CR mice in spite of identical energy intake. Lifespan was also 
longer in the CR mice. Surprisingly lifespan was shorter in the CR-high mice than in those on the 
regular diet.  (Cai 2008).  This is a very surprising finding, one that points out the urgency of 
finding out what impact AGE could have in humans. 
 A few longer interventions in humans have been reported. In one study overweight and 
obese individuals were randomized to a crossover trial involving two weeks on a low and high 
AGE diet (Harcourt 2011). Only 11, male participants aged 18 to 50 were involved in this study. 
Fat was held constant between the two diets at 30% with AGE being the primary variable; 
however, AGE was calculated based on the Goldberg study. Foods consumed were similar but 
not identical. For example, the low-AGE lunch might include an apple and an avocado and ham 
sandwich without crusts with diet lemonade whereas a high-AGE lunch might include one apple 
and a toasted bacon sandwich with crusts and with a cola beverage. The primary outcome was 
renal function, and the researchers found that albumin to creatinine ratios were improved 
following the low AGE diet in obese individuals. Plasma AGE increased following high AGE 
consumption. Plasma monocyte chemoattractant protein-1 (MCP-1) was increased after 
consumption of the high AGE diet as was the plasma macrophage migration inhibitory factor 
(MIF). Other cytokines were no different including soluble RAGE (sRAGE),  NF-ĸβ, Interleukin-
6 (IL-6) and CRP (Harcourt 2011). Some drawbacks to this study design include likely 
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differences in type of fat in the study due to the dietary approach used. The distribution of 
calories from various types of fat (saturated, monounsaturated, polyunsaturated) was not 
described in this study; however, given that the low-AGE meal plan seems to be very low in fat 
yet diet composition was retained at 30% fat, it appears that the addition of olive oil and avocado, 
both mono-unsaturated fats, to some meals, was used to maintain this percentage. This may 
confound inflammatory data given that saturated fats are thought to be inflammatory (Holzer 
2011). 
 Vlassara et. al. performed a similar type of study involving two arms: one consisting of a 
two week crossover trial involving 11 diabetic subjects and another involving 13 diabetic subjects 
in a 6 week study (Vlassara 2002). In this study the diets had similar calorie, protein and fat 
percentages but differed 5 fold in CML content. The high AGE diets met National Cholesterol 
Education Program Step 1 diet guidelines and American Diabetes Association guidelines. Thus 
they were not high in saturated fat (<10%). Serum AGE was measured by ELISA for CML.  In 
the crossover trial, subjects followed either a low or high AGE diet for two weeks, had a one 
week washout period, then consumed the high AGE diet for two weeks. Both diets were low in 
fat, differing only in AGE content.  For the six week trial, the 13 subjects were randomized to 
either the low or high AGE diet for 6 weeks, creating very small study groups. However, CRP 
increased by 35% on high AGE diet and decreased by 20% on low AGE. VCAM-1 decreased by 
20% on low AGE and increased by 4% on high AGE. Serum AGEs increased by 28% on high 
AGE and were reduced by 40% on low AGE. Unfortunately almost no data on the dietary 
interventions was included with this report, making it difficult to evaluate any confounding 
dietary factors which may have been present.  
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Mechanisms of Damage Caused by AGE 
 
A key review study by Brownlee has defined ways in which AGEs may damage target 
cells leading to diabetic complications. Three primary means of damage were defined. 
1) Modification of cellular proteins by glycation could modify their function as well.  
2) Extracellular proteins or other molecules modified by AGE might interact differently 
with their receptors. 
3) Receptor mediated AGE oxidative processes may also cause cellular damage. 
(Brownlee 2001).  
Most mechanistic explanations of how AGE may cause oxidative damage suggest that 
AGEs exert influence via receptors. RAGE receptors may be expressed on the surface of a variety 
of cells including neurons, monocytes, endothelial cells, fibroblasts and more (Kalousova 2005).  
The RAGE receptor may then activate signal transduction pathways including extracellular signal 
related kinase (ERK kinase), mitogen activated protein kinases (p38 
MAPK
), c jun terminal kinases 
(JNK kinases) and nuclear factor kappa beta (NF-ĸβ).  Thus, transcription of genes may be 
stimulated which will up-regulate production of growth factors such as TNF-α, IL-1 and IGF-1 
and adhesion molecules such as ICAM-1 and VCAM-1. In addition, it is suggested that DNA 
may also undergo glycation. Thus, AGE modification of DNA could affect regulatory and 
epigenetic processes at the DNA level (Ramasamy 2005).  
Alternatively, in individuals some RAGE may be differentially spliced, forming soluble 
RAGE (sRAGE) which may act as a decoy receptor aiding in secretion of AGE (Barlovic 2011). 
sRAGE may actually consist of two isoforms: ―the extracellular domain of wild type full-length 
RAGE, which results from proteolytic cleavage at the cell surface‖ and ―an endogenous secreted 
isoform lacking a transmembrane domain‖ (Colhoun, 2011): sRAGE and esRAGE, respectively.  
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In addition, it has been discovered that the RAGE receptor has multiple ligands and that 
during an inflammatory response, the binding of the ligand to RAGE actually leads to increased 
expression of RAGE (Fritz 2011). This is one means by which a short-term inflammatory 
response could become a chronic state. The ligands for RAGE identified so far include AGEs, 
S100 proteins (a protein family consisting of 25 members which have metal ion binding 
properties), amyloid beta and amyloid fibrils, high mobility group box 1 protein (HMGB1) and 
beta2-integrin macrophage-1 antigen (Fritz, 2011).  Thus, questions remain regarding whether all 
ligands for RAGE have been identified, which are most important, and how they may interact or 
compete with the RAGE receptor.  
Other mechanisms of AGE damage have also been proposed. LDL modification by 
endogenous AGEs may be a contributing cause to the cardiovascular disease often seen in 
subjects with diabetes; however dietary AGEs may also contribute. One study of 24 participants 
with diabetes who followed a high AGE or low AGE diet for 6 weeks found that LDL from the 
patients on the high AGE diet was more glycated.  In addition, when this glycated LDL was 
added to human umbilical vein (HUVEC) cells, ERK 1/2 was phosphorylated in a time and dose 
dependent manner compared to low AGE LDL or native LDL. Likewise, NF-ĸB was also 
stimulated by high AGE LDL. (Cai 2004) 
In both cellular models and in Sprague-Dawley rats and non-obese diabetic mice 
subjected to AGE treatment or ingestion, AGEs were found to be toxic to the beta cells of the 
pancreas. Beta cells exposed to AGEs developed glucose stimulated insulin secretory defects and 
loss of manganese superoxide dismutase (MnSOD) activity. Rats exposed to AGEs developed 
progressive insulin secretory defect, generation of superoxide, and beta cell death (Coughlan 
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2011).  Which mechanisms of AGE damage will be determined to be most important may depend 
somewhat on the age and health of the population in question.  
INTERRELATIONSHIPS: BMI, AGE, sRAGE, AND DISEASE 
It has become fairly well established that AGE may contribute to oxidative stress in renal 
disease and diabetes  and that endogenous AGE production is increased in diabetes and excretion 
inhibited in chronic kidney disease (Ramasamy 2005; Semba 2009; Brownlee 2001). In addition, 
literature suggests that AGEs are involved in inflammatory processes (Ramasamy 2005; 
Brownlee 2001).  The extent to which elevated circulating AGEs are the cause or symptom of 
disease and how AGEs, RAGE and sRAGE may be influenced by factors such as body fatness 
and lifestyle is less clear. 
In several studies, fatness and sRAGE do appear to be linked. Koyama et. al. reported an 
inverse correlation of components of the metabolic syndrome with sRAGE. Components 
demonstrating this inverse relationship included body mass index, TG, HbA1c and insulin 
resistance with BMI in both diabetic and non-diabetic participants. This study involved 203 
participants, but notably, the population was homogenous (Japanese), older (~56 years of age), 
and with a narrow BMI range (BMI 23.2 ± 3.3) (Koyama 2005). Another Japanese group also 
found sRAGE to be inversely correlated with BMI, waist circumferences, AGE intake and 
alcohol intake (Yamagishi 2006). This study involved 184 non-diabetic subjects. This group was 
again homogenous (Japanese), older (66.7 ± 9.1) and with a narrow BMI range (23.2 ± 3.7). CML 
was used as a proxy for AGEs in this study.  
Norata et. al. also reported that sRAGE was inversely correlated with BMI, waist/hip 
circumference and fasting glucose with a positive correlation in apolipoprotein A-1. This study 
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included 176 healthy subjects. Again participants were homogenous (Italian), older (mean age of 
62.4 ± 11.6 years), but with a somewhat wider BMI range (BMI 27.4 ± 3.6). (Norata 2009) 
A third study by Semba et. al. used DEXA to establish body fatness and found that total 
fat mass, truncal fat mass and appendicular fat mass were each inversely associated with serum 
CML when age, sex, BMI, blood pressure, TG, HDL and renal function were controlled for. This 
suggests that body fat affects CML and possibly other AGEs perhaps because AGEs may be 
stored in fatty tissue (Semba 2011). This study involved 592 men and women who were older 
(age 55-75), 62% Caucasian with a BMI range of 23-31.  Thus, the link between sRAGE and 
fatness seems to be established based on several studies done in separate populations. This 
suggests one possible strategy to improve serum sRAGE concentrations might be the perpetual 
lifestyle modification recommendation: weight loss.  
It has also been noted in a recent review that two studies have found statins to raise 
sRAGE levels and another statin trial has found no effect (Ramasamy 2011). sRAGE levels have 
also been linked to white race, and higher adiponectin levels, but dietary influences on sRAGE 
have not been evaluated (Ramasamy 2011).  
A study by Diamanti-Kandarakis et. al. found a correlation between AGEs and BMI. This 
study involved 60 women aged ~20-32 with BMI 19-24 (Diamanti-Kandarakis 2009). The study 
described here earlier by Yamagishi et. al. also described a link between AGEs and BMI. Given 
more limited data in this area, the link between AGEs and fatness is suggestive.  
Finally the study by Yamagishi et. al. also identified a correlation between sRAGE and 
AGE. However, they found a positive correlation between the two. This seems counter-intuitive 
given research suggesting the AGEs are increased with increasing BMI whereas the link is 
opposite for sRAGE. This group of researchers hypothesized that sRAGE may reflect tissue 
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RAGE expression and that sRAGE may increase along with AGE in order to mount a counter-
defense (Yamagishi 2006).   
A separate Japanese study found a relationship between AGE and esRAGE in 107 
patients with type 2 diabetes. Serum AGE and sRAGE were both highest among participants with 
diabetes who were also on hemodialysis. Serum esRAGE was correlated with BMI, duration of 
diabetes, serum creatinine, high density lipoprotein and CML and pentosidine in this study 
(Gohda 2008).  
However, in a study of older, Caucasian, Swedish men, CML concentrations were not 
related to sRAGE nor to energy, carbohydrate, total fat, type of fat, or vitamin intake. In this 
study BMI and endothelial cell activation were found to be linked, but sRAGE and endothelial 
activation were not. The relationship between BMI and sRAGE or CML was not reported in this 
study (Sjogren 2007).  Thus, the relationship between AGE and sRAGE seems a bit tenuous for 
now. Further work needs to be done in this area. 
In addition, consistency of sRAGE/esRAGE data is questionable. One head to head 
comparison of these two forms of RAGE: sRAGE and es RAGE has been done in a German 
population. In it 110 persons with type 2 diabetes were recruited and subjected to three 24 hour 
urine collections and fasting blood tests. In this study sRAGE and esRAGE were found to be 
correlated by only at r=0.57. esRAGE levels were five times lower than sRAGE values. Very 
little was decided in this study given that sRAGE and es RAGE were not shown to be associated 
with glucose control or macrovascular disease (Humpert 2007).  
An animal model developed by Ueno and Koyama has sought to determine whether 
RAGE is involved in adiposity and to explore the relationship of RAGE with progression of 
atherosclerosis (Ueno 2010). C57BL/6J RAGE 
+/+
 and RAGE 
-/-
 mice were produced, crossed and 
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intercrossed to generate ApoE
-/-
RAGE
+/+ 
and ApoE
-/-
RAGE
-/-
 mice. These mice were then 
randomly assigned to atherogenic diet (20% of kcals from coca butter ) and standard chow diet 
from 6 weeks to 20 weeks of age. The ApoE
-/-
RAGE
-/-
 mice fed with either diet had decreased 
plaques even though no differences in cholesterol or glucose were observed. The ApoE
-/-
RAGE
-/-
 
mice also gained significantly less body weight despite a lack of difference in food intake. 
Researchers also found that plaque area was positively associated with epididymal fat weight and 
negatively with serum adiponectin. Thus, it appears that mice who are deficient in RAGE have 
improved body fatness and less atherogenesis, an intriguing finding should it also be found to be 
true in humans. 
Other relationships of AGE to metabolic indicators have also been described. In a study 
of 51 Greek women, of which 29 had PCOS, AGE was found to be higher in the women with 
PCOS. AGE was also found to be increased in women with increased testosterone levels. A 
positive correlation was also noted between AGE and free androgens, waist to hip ration, insulin, 
HOMA and RAGE. Negative correlations with AGE were observed for glucose/insulin ration and 
the quantitative insulin sensitivity check index (QUICKI). (Diamanti-Kandarakis 2005).  
AGEs AND ADIPONECTIN 
A less well studied area of AGEs research involves how AGEs and adiponectin relate. 
Adiponectin is an adipokine, or hormone released from adipose tissue, which is decreased in 
diabetic subjects and those with elevated BMI (Rosen 2006; Hotta 2000). In a study of 108 
overweight patients, CML was found to inversely correlate with adiponectin levels. Furthermore, 
adiponectin seems to be protective against endothelial dysfunction induced by AGEs (DelTurco 
2011). However, within the field of adiponectin research there is disagreement over which form 
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of adiponectin is the active form of hormone given that adiponectin circulates in multimeric 
forms (Rosen 2006).  
Another human study in a Korean population found sRAGE to correlate with 
adiponectin, IL-6 and to be inversely correlated with BMI, waist circumference, blood pressure, 
triglyceride, fasting glucose level and insulin resistance.  They also found lower sRAGE levels in 
participants with type 2 diabetes. (Choi 2009) 
One group of investigators has tried to evaluate how AGEs may modify serum 
adiponectin concentrations. This group hypothesized that since oxidative stress has been known 
to decrease adiponectin levels in rats and since AGE-RAGE interaction may increase oxidative 
stress, AGE-RAGE interaction may induce adiponectin gene suppression (Maeda 2011). To study 
this effect, they used pigment epithelium-derived factor (PEDF), a glycoprotein which is known 
to block AGE-RAGE induced inflammatory reactions in cells, to treat differentiated adipocytes 
which had also been treated with AGE. They found that AGEs increased oxidative stress in the 
adipocytes but that this effect was blocked by PEDF. The AGEs up-regulated decreases in 
adiponectin mRNA, and the PEDF treatment completely ameliorated this effect. 
This area of research is particularly intriguing as this may another way in which AGEs 
exert their detrimental physiological effects: via suppression of adiponectin. This also poses a 
possible therapy for persons with diabetes: lowering of AGEs within the diet in order to up-
regulate adiponectin and suppress AGE-related cellular damage.  
MACRONUTRIENT INTAKE, AGE, AND INFLAMMATORY MARKERS 
 Another area of research yet to be fully elucidated in the field of AGE/RAGE biology and 
nutrition includes the interaction between dietary macronutrient composition and serum AGE and 
sRAGE. Much has been made of the importance of low fat diet in lowering risk of cardiovascular 
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disease. However, cooking methods recommended for lowering fat intake such as broiling, 
grilling and roasting tend to increase concentrations of advanced glycation end products (AGEs) 
in foods. Current research suggests that AGEs increase oxidative and carbonyl stress, may 
decrease cardiovascular endothelial dysfunction, and contribute to cellular damage related to 
diabetes and chronic kidney disease. In addition increased body fat and body weight are 
associated with higher levels of AGE and decreased levels of an important receptor for AGE 
(sRAGE). AGE in the diet has also been associated with increased levels of CRP (Uribarri, Cai 
2007).   
 Since low fat diet is often recommended for weight control in obese and overweight 
persons, it is important to determine to what extent a low fat diet using these commonly advised 
cooking methods may contribute to AGE load and whether such a low-fat diet may negatively 
affect inflammatory cytokines thought to be influenced by AGE. It is also unclear whether dietary 
AGE influences sRAGE.  Does the body have some capacity to compensate for high AGE intake 
with higher sRAGE?  In fact, given recent data suggesting there is no relationship between 
dietary AGE and serum AGE, it needs to be confirmed that dietary CML will result in increased 
serum CML.  In the context of different types of diets which are isocaloric, will a low fat diet 
cooked using high heat methods have equivalent amounts of AGE compared to a high fat diet 
cooked in these ways? Will consumption of a low fat diet using these cooking methods have the 
same effects on serum AGE and sRAGE compared to a high fat diet?   
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CHAPTER III 
METHODS FOR STUDY I AND II 
These studies were approved by the Institutional Review Board Human Subjects Review 
Committee at Texas Woman’s University (Appendices A and B).  
STUDY I 
Participants 
 Study I was part of a larger study. Briefly, 77 healthy adult participants between the ages 
of 20 and 45 were recruited from the Texas Woman’s University campus community. Exclusion 
criteria included self-reported hypertension, hypercholesterolemia, diabetes, heart disease, kidney 
disease, cancer or metabolic disease. Smokers and those taking any medication which could 
affect blood lipids or glucose levels were also excluded.  Frozen fasting sera were used for 
analysis.  
Anthropometric and Biochemical Measurements 
Potential participants reported to the research location on a Saturday morning following a 
twelve hour overnight fast. After obtaining informed consent, participants were screened. 
Anthropometric measurements (height, weight, waist circumference) were done by the same 
personnel.    
  Weight was measured to the nearest 0.1 pound using a beam scale, height to the nearest 0.25 
inch using a stadiometer, and waist circumference to the nearest 0.25 inch at the level of the hip 
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bone using two consecutive measures with a non-elastic tape.  Measurements were converted to 
metric units for reporting purposes. 
  A phlebotomist obtained fasting blood, which was then allowed to clot for 30 minutes and 
centrifuged at 3600 rpm for 15 minutes. Sera were separated, aliquoted and stored at -80
0
 C until 
assayed.  
Blood Sample Analysis 
 Sera were analyzed for triacylglycerol (TG), total cholesterol (TC), high density lipoprotein 
(HDL), and glucose using commercially available kits (StanBio, Boerne, TX).  LDL was 
calculated using the Friedewald Equation ([LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/5)). 
Adiponectin, insulin and HMW adiponectin were measured using enzyme linked immunoassay 
kits (ELISA) (RayBiotech, Norcross, GA; Alpco, Salem, NH; Alpco, Salem, NH).  CML and 
sRAGE were also measured using ELISA (Microcoat, Bernried, Germany; Biovendor, Karasek, 
Czech Republic). See Appendix C for the methods used for these analyses.  
Statistical Analyses 
Potential numerical outliers were identified using box plots and 1.5 times the Q1 to Q3 
interquartile range. Data were analyzed with and without outlier data for comparison. Pearson’s 
correlations were performed for all sera and anthropometric parameters. SPSS version 19.0 for 
Windows was used to perform statistical analyses including descriptive statistics, analysis of data 
for normality, and correlations.  
Based on the techniques to identify outliers outlined above, the data from five (5) 
participants were excluded. Reasons for exclusion from the study group included having extreme 
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values for sRAGE (n=2), CML (n=2), or insulin (n=1). Statistically significant relationships were 
present when outlier data was included; however, the strength of the correlations were slightly 
increased when outlier data was excluded. 
STUDY II 
Participants and Recruiting 
 Male and female adult participants ages 20-45, BMI 27-35 (overweight or class 1 obesity) 
without self-reported hypertension, heart disease, diabetes, kidney disease, metabolic disease or 
cancer were recruited from the TWU campus community and the larger Denton community. 
Methods of recruitment included use of course advertisements through the course management 
system for the University, Portal announcements geared toward TWU faculty, staff and students, 
and print announcements on university bulletin boards. In addition, local doctor’s offices, primarily 
family practice physicians, were contacted and asked to share the flyer with eligible, interested 
patients. Local gyms, clubs and community organizations were also contacted and asked to share 
information about the study with their members. A Facebook page was created in which updates 
and announcements were provided. Instructors at the University of North Texas were also contacted 
and asked to share information about the study with their students. See Appendix D for copies of 
the recruitment flyer and Portal/Facebook flyer. 
Interested potential participants contacted the primary researcher by phone or e-mail. If 
the first contact was by phone, the researcher requested the potential participant’s e-mail address 
in order to send information on study criteria and how to determine study eligibility. Interested 
potential participants contacted the researcher again to set a time to meet with the participant on 
campus, explain and sign the consent form, and complete the screening process.  Following the 
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completion of informed consent, participants were screened to see if they met study criteria, 
including being free of hypertension, diabetes, cardiovascular disease, kidney disease, cancer, or 
metabolic disorders. Only participants without significant medical histories were allowed to 
participate. Smokers were excluded from the study, as were those taking anti-inflammatory 
medications, lipid lowering drugs, or those who were pregnant or lactating. After screening was 
complete, participants were assigned a time to come to campus for the study. See Appendix E for 
a sample of the scripts for contact with the researcher, the study flyer, and the electronic version 
of the study flyer. See Appendix F to review the form used for screening participants.  
Nutrition Instrument 
Participants were instructed to fill out a five-day food record based on the five days 
immediately preceding the study.  A food journal form was used for this purpose. (See Appendix 
G for an example of the food journal.)  
Anthropometric, Biochemical Measurements and Study Protocol  
  All participants were scheduled to consume both study diets. Diet A was a low-fat, high 
AGE diet (LFHA).  Diet B was a high fat, high AGE diet (HFHA). Each diet was consumed for 
one day with a series of blood draws following the first test meal and a follow-up fasting blood 
draw the day after consumption of the test diet. A two-week washout period was inserted between 
each test day’s diet. Please see additional information on the diet in the next section ―Diet 
Intervention‖.  
  On day one of the study, participants reported to the lab for anthropometric 
measurements. A portable stadiometer was used to measure height to the nearest one-quarter inch, 
and a beam scale was used to measure weight to the nearest 0.5 pound. Height and weight 
measurements were converted to centimeters and kilograms for reporting, and body mass index 
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(BMI) was calculated in kg/m
2
. Waist circumference was measured with a non-stretch tape measure 
to the nearest 0.5 cm at the narrowest part between the lower costal (10
th
) rib border and iliac crest. 
Finally, percentage body fat was measured using bioelectrical impedance analysis (BIA) using a 
Tanita electronic scale. See Appendix H for a copy of the data collection form.  
Five blood draws were conducted during each phase of the study. The first blood draw 
was done at baseline during the first trip to the lab with follow-up blood draws to include 1 hour, 
2 hour and 3 hour post-prandial draws after consumption of the first test breakfast meal. After 
completion of the 3 hour post-prandial blood draw, participants consumed lunch. They consumed 
an afternoon snack, dinner and a bedtime final snack over the course of the remainder of the day 
and returned to the lab the next morning for another fasting draw.  
After a two week wash-out period, participants returned to campus for the second phase 
of the study. Anthropometric measurements were done immediately prior to the second 
dietary intervention period by the same personnel. The same protocol was used for both 
dietary interventions. Each blood draw was be performed by a trained nurse or certified 
phlebotomist.  
Diet Intervention 
Participants received two isocaloric study diets: one containing 20% of calories from fat, 
the other with 41% of calories from fat. The fatty acid distribution of both diets was 1:2:1 
(MUFA:PUFA:saturated fat). High AGE cooking methods were used for each: broiling, roasting, 
baking, and frying. See Appendix I for a copy of the menus. 
Study foods were prepared in the Food Preparation Laboratory or Sensory Laboratory 
and were provided for breakfast, lunch and dinner daily during the two one-day study periods. 
Food was consumed in the lab or boxed and given to the participant to be consumed at home 
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according to the need of the participant.  Dietary macronutrient content was calculated initially 
using Nutritionist Pro, then confirmed by proximate analysis by an independent laboratory: Pope 
Labs. See Appendix J for a copy of the analyses. AGE content in study foods was calculated 
initially using the tables of Uribarri (2010). It was later measured using ELISA and was compared 
using several methods to prepare foods for AGE ELISA analysis. See Appendix K for methods  
to analyze AGE in the study foods. Participants were allowed to eat only the study foods during 
each day-long intervention period. 
Biochemical Analysis 
  Sera were analyzed for glucose, triacylglycerol (TG), total cholesterol (TC), and high 
density lipoprotein (HDL) using commercially available kits (StanBio, Boerne, TX).  LDL was 
calculated using the Friedewald Equation ([LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/5)). 
HMW adiponectin was measured using enzyme linked immunoassay kits (ELISA) (Alpco, 
Salem, NH).  CML, CRP, and sRAGE  were also measured using ELISA (Microcoat, Bernried, 
Germany; Alpco, Salem, NH; Biovendor, Karasek, Czech Republic). See Appendix B for the 
methods of these analyses, Appendix L for CRP.  
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CHAPTER IV:  
SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) 
CORRELATES INVERSELY WITH INDICATORS OF ADIPOSITY 
A Paper to Be Submitted for Publication in Acta Diabetologica 
Kathleen E. Davis 
ABSTRACT 
Obesity is a public health crisis because of its high incidence and its link to diabetes and 
cardiovascular disease, conditions associated with an inflammatory state. Advanced glycation 
endproducts (AGEs) may contribute to inflammation within the body by interacting with the 
receptor for AGEs (known as RAGE), but the soluble receptor for this compound may reduce 
serum concentrations, thereby decreasing oxidative stress.  The purpose of our study was to 
explore the relationship among measures of adiposity, AGEs, and their soluble receptor in a 
diverse group of healthy young adults. Anthropometrics were obtained from 72 participants, and 
sera were analyzed for n-(epsilon)-(carboxymethyl)-lysine (CML), a measure of advanced 
glycation endproducts and for sRAGE (n=72). Total adiponectin, high molecular weight (HMW) 
adiponectin, insulin, total cholesterol, high density lipoprotein, and triacylglycerol were also 
assessed. sRAGE was inversely correlated with weight (r= -0.364; p=0.002), waist circumference 
(r= -.334; p=0.004), and body mass index (BMI) (r= -0.364; p=0.002). This is the first time such 
associations have been found in a group of ethnically-diverse, healthy, young adults. HMW 
adiponectin also correlated with sRAGE (r=0.416; p=0.02). Controlling body weight and 
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improving insulin resistance, factors tied to adiponectin concentrations, may reduce inflammation 
via up-regulation of sRAGE. 
INTRODUCTION 
During the past several decades, obesity has become a public health crisis [1-2], and the 
incidence of obesity has risen at an alarming rate in both industrialized and developing countries. 
Currently, 67% of Americans are either overweight or obese. Obesity has been clearly linked to 
diabetes and cardiovascular disease and as such is an important public health issue [3].  As 
obesity and sedentary lifestyle have increased, so have the prevalence of other inflammation-
related conditions such as type 2 diabetes and metabolic syndrome, which are characterized by 
abdominal obesity, hyperlipidemia, hypertension and insulin resistance [2].  
Advanced glycation endproducts are a family of compounds formed when reducing 
sugars react with amino acids or other substances, forming glycosylated molecules.  They may 
contribute to oxidative stress within the body by interacting with the receptors for advanced 
glycation endproducts (RAGE), the immunoglobulin super family of receptors [4]. RAGE has a 
single trans-membrane domain followed by a cytosolic tail with the N-terminus of the V domain 
acting as the ligand binding site, and the cytosolic tail functioning in RAGE-induced intracellular 
signaling [5-6]. Truncated forms of RAGE have also been reported which may result from 
alternative mRNA splicing or proteolytic cleavage from the cell surface [5]. The variant which 
lacks both the cytosolic and the trans-membrane domains is called the soluble receptor for 
advanced glycation end products (sRAGE) [5-7]. Because sRAGE retains its ability to bind 
circulating ligands, it may play an important role in attenuating the adverse effects associated 
with RAGE signaling [5]. 
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 RAGE is widely expressed in a variety of tissues (heart, lung, skeletal muscle, and vessel 
wall) and cell types (monocytes/macrophages and lymphocytes) [4]. The activation of RAGE by 
its ligands (including AGEs) results in induction of oxidative stress and expression of pro-
inflammatory cytokines and chemokines. Therefore, serum sRAGE has the potential to diminish 
AGE-RAGE interaction by binding circulating AGEs, resulting in decreased inflammation [6, 8]. 
In addition, AGE-RAGE signaling may be decreased via up-regulation of circulating sRAGE [5-
6]. 
 Obesity is a public health crisis because of its high incidence and its link to diabetes and 
cardiovascular disease.  Obesity is characterized by a chronic, systemic state of low-grade 
inflammation. Thus, it is logical to assume that sRAGE signaling may be reduced in obesity and 
even in overweight conditions. Studies done in older, homogenous populations of adults and 
children suggest that sRAGE is depressed in obese individuals compared to normal weight 
individuals [9-16]. In addition, sRAGE is currently being evaluated for its utility in identifying 
cardiometabolic risk in populations from adults to children [13, 17-19]. However, the relationship 
of sRAGE with factors which may predict its levels have only been partially uncovered. In 
several studies sRAGE has been inversely correlated with obesity. However, none of these 
studies has been done in a diverse population.  Moreover, there is conflicting data in the literature 
regarding sRAGE and abdominal adiposity in children and older adults [9-16].  Therefore, this 
study investigated the relationship among  n-(epsilon)-(carboxymethyl)-lysine protein, a measure 
of advanced glycation endproducts, sRAGE, and indicators of adiposity in a group of young, 
healthy, ethnically diverse adults.  
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METHODS AND MATERIALS 
This study was approved by the Texas Woman’s University Institutional Review Board’s 
Human Subjects Committee. Seventy-seven healthy adult participants between the ages of 18 and 
45 were recruited from the university community. Exclusion criteria included self-reported 
hypertension, hypercholesterolemia, diabetes, heart disease, kidney disease, cancer or metabolic 
disease. Smokers and those on lipid- or glucose-lowering medications were also excluded.  
Participants reported to the research location following a twelve hour fast. After obtaining 
informed consent, participants were screened for inclusion and exclusion criteria. Anthropometrics 
(height, weight, and waist circumference) were obtained for subjects selected for the study, and 
fasting blood was collected, allowed to clot for 30 minutes, centrifuged at 3600 rpm for 15 minutes, 
and stored at -80
0
 C.  
  Sera were analyzed for triacylglycerol (TG), total cholesterol (TC), and high density 
lipoprotein (HDL) using commercially available kits (StanBio, Boerne, TX).  LDL was calculated 
using the Friedewald Equation ([LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/5)). Total 
adiponectin, insulin, high molecular weight (HMW) adiponectin, CML and sRAGE were 
measured using enzyme-linked immunoassay (ELISA) kits (RayBiotech, Norcross, GA; Alpco, 
Salem, NH; Alpco, Salem, NH; Microcoat, Bernried, Germany; BioVendor, Karasek, Czech 
Republic, respectively).   
Potential numerical outliers were identified using box plots and 1.5 times the Q1 to Q3 
interquartile range. Data were analyzed with and without outlier data for comparison. Pearson’s 
correlations were performed for all sera and anthropometric parameters. SPSS version 19.0 was 
used to perform statistical analyses including descriptive statistics, analysis of data for normality, 
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and correlations. ANOVA was used to compare differences in parameters based on BMI 
classification and waist circumference. 
RESULTS 
 Of 77 participants from whom data were obtained, 72 were included in the study. Five 
subjects were excluded due to having extreme values for sRAGE (n=2), CML (n=2), or insulin 
(n=1).  The study population included 22 male subjects (Age: 26.4 ± 4.5 years; Ethnicity: Asian 
41%, Caucasian 36%, Hispanic 18%, African-American 5%; Body Mass Index (BMI): 23.9 ± 
2.0; Overweight and Obese: n=6) and 50 female subjects (Age: 23.6 ± 5.2 years;  Ethnicity: Asian 
18%, Caucasian 52%, Hispanic 14%, African-American 14%, Other 2%; BMI: 24.3 ± 4.2; 
Overweight and Obese: n=18).  A greater proportion of females in the study were overweight 
(36% compared to 27% for males). While the BMI differences between the sexes were not 
statistically significant, the groups were significantly different in age (p=0.04).  
While participants’ biochemical data was noted to be different between males and 
females for HDL  (Males: 1.04 mmol/L ± 0.28, Females: 1.35 ± 0.31, p=0.007), TG (Males: 1.11 
mmol/L ± 0.54; Females: 0.64 ± 0.44, p=0.01), and HMW adiponectin (Males: 1.9 µg/ml ± 1.2, 
Females: 3.2 ± 1.8, p=0.03), there was no difference with regard to TC (Males: 4.43 mmol/L ± 
0.83, Females: 4.09 ± 0.78), adiponectin (Males: 0.54 µmol/L ± 0.57; Females 0.52 ± 0.37), 
insulin (Males: 34.7 pmol/L ± 13.9; Females: 43.8 ± 31.3),  CML (Males: 722 ng/mL ± 198, 
Females: 844 ± 323) or sRAGE (Males: 552 pg/ml ± 223, Females: 626 ± 256). 
Factors inversely correlated to sRAGE included weight (R= -0.364; p=0.002), waist 
circumference (R= -0.334; p=0.004), and BMI (R= -0.364; p=0.002). As is shown in Table 1, 
HMW adiponectin was positively correlated with sRAGE concentrations (0.416; p=0.02).  When 
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ANOVA was used to compare BMI classification with sRAGE, sRAGE was significantly 
different only when comparing normal weight to obese participants, but there is a non-significant 
decrease in sRAGE as BMI increases (Figure 1). In addition, sRAGE was found to be 
significantly different between participants with a high waist circumference (>102 cm in men; 
>88 cm in women) indicating increased health risk compared to those with normal waist 
circumference (p=0.03).   
Using linear regression model, HMW adiponectin, TC, BMI and CML were found to be 
significant predictors of sRAGE. However, when combined, these predictors explained only 47% 
of the variance in sRAGE as other factors such as dietary intake of AGEs, undetermined genetic 
factors or underlying health  status may also influence sRAGE.  
DISCUSSION 
In the present study, we have reported for the first time a strong, inverse relationship 
between measures of adiposity and circulating sRAGE in young adults of diverse ethnicity 
between ages 18 and 40. Our observations are similar to those reported in four earlier studies in 
homogenous older Japanese and Italian adults of mean age 45 to 66 years [9-12] and in children 
[13].   In contrast to these studies, our study did not find an inverse correlation between sRAGE 
and glucose, insulin, or TG in young, healthy ethnically-diverse adults. 
Our study points to a number of similarities and differences compared to results reported 
by others [10-16]. Unlike Choi [14] we found a significant correlation between sRAGE and 
HMW adiponectin, but not total adiponectin.  Whereas Del Turco et. al. found an inverse 
correlation between CML and adiponectin [15], this finding was not observed in our data. 
However, similar to Yamagishi [10], we found a positive correlation between CML and sRAGE. 
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(R=0.237, p=0.05). Also, we did not find an inverse relationship between CML and adiposity as 
did Semba et. al. [16].  
sRAGE appears to be an anti-inflammatory marker, correlating inversely with body 
weight and positively with HMW adiponectin. However, it also correlates positively with CML, 
which is thought to be a pro-inflammatory surrogate marker of AGEs. One explanation for this 
anomalous observation may lie in possible induction of sRAGE by increasing CML load. 
Because oxidative stress decreases adiponectin expression, Maeda et. al. hypothesized 
that AGE-RAGE interaction may further exacerbate oxidative stress by suppressing the 
adiponectin gene [20]. These investigators reported that AGEs increased oxidative stress in rat 
adipocytes and that AGEs down-regulated adiponectin mRNA. This area of research is 
particularly intriguing as this may be another way in which AGEs exert their detrimental 
physiological effects: via suppression of adiponectin. This may be a potential therapy for persons 
with diabetes: lowering of AGEs within the diet in order to up-regulate adiponectin and suppress 
AGE-related cellular damage. 
 One limitation of our preliminary study is that we used CML as an indicator of AGE 
although there are several indicators of AGE.  CML measurements have been found to correlate 
well with other markers of AGE [21-23].   
While our observation of the relationship between sRAGE and adiposity in a young 
population is similar to earlier studies with older subjects, the relationships observed among other 
markers related to adiposity (glucose, insulin, adiponectin, Chol, TG) are dissimilar in many 
cases. The underlying reasons for these apparent discrepancies may lie in the differences in the 
study population with respect to ethnicity, age, and underlying health status. 
40 
 
ACKNOWLEDGEMENTS 
 This research was supported by Human Nutrition Research Fund of the State of Texas. 
 
CONFLICT OF INTEREST 
 None. 
REFERENCES 
1. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US 
adults: findings from the Third National Health and Nutrition Examination Survey. 
JAMA 287:356-359. 
2. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. (2000) The 
continuing epidemic of obesity in the United States. JAMA 284:1650-1651. 
3. Isomaa B, Almgren P, Tuomi T, et. al. (2001) Cardiovascular morbidity and mortality 
associated with the metabolic syndrome. Diabetes Care 24: 263-289. 
4. Ramasamy R, Vannucci SJ, Shi Du Yan S, Herold K, Fang Yan S, Schmidt AM (2005) 
Advanced glycation end products and RAGE: a common thread in aging, diabetes, 
neurodegeneration, and inflammation.  Glycobiology  15 (7): 16R-28R. 
5. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, 
Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts 
(RAGE) is produced by proteolytic cleavage of the membrane-bound form by the 
sheddase a disintegrin and metalloprotease 10 (ADAM10).  FASEB J  22:3716-3727.  
41 
 
6. Kalea AZ, Schmidt AM, Hudson BI (2011) Alternative splicing of RAGE: roles in 
biology and disease.  Front Biosci 16, 2756-2770. 
7. Ramasamy R, Yan S-F, Schmidt AM (2012) Advanced glycation endproducts: from 
precursors to RAGE: round and round we go.  Amino Acids 42 (4): 1151-1161. 
8. Fritz G (2011) RAGE a single receptor fits multiple ligands. Trends in Biochem Sci 
36(12):625-632. 
9. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji 
T, Tamei H, Matsuki H, Sakurai S, YamamotoY, Yonekura H, Watanabe T, Yamamoto 
H, Nishizawa Y (2005) Plasma level of endogenous secretory RAGE is associated with 
components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc 
Biol 25: 2587-2593. 
10. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, 
Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T (2006) Positive association 
between serum levels of advanced glycation end products and the soluble form of 
receptor for advanced glycation end products in nondiabetic subjects. Metabolism  55: 
1227-1231. 
11. Norata GD, Garlaschelli K, Grigor L, Tibolla G, Raselli S, Redaelli L, Buccianti G, 
Catapano AL (2009) Circulating soluble receptor for advanced glycation end products is 
inversely associated with body mass index and waist/hip ratio in the general population.  
Nutr, Metab,Cardiovasc Dis 19: 129-134. 
12. Vazzana N, Guagnana MT, Cuccurullo C, Ferrante E, Lattanzio S, Liani R, Romano M 
and Davi G (2012) Endogenous secretory RAGE in obese women: association with 
platelet activation and oxidative stress.  J Clin Endocrin Metab 97 (9):E0000-E0000. 
42 
 
13. Giorgis T, D’Adamo E, Giannini C, Chiavaroli V, Scarinci A, Verrotti A, Chiarelli F, and 
Mohn A (2012) Could receptors for advanced glycation end products be considered 
cardiovascular risk markers in obese children? Antioxid and Redox Signal 17 (2): 187-
191. 
14. Choi K, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH 
(2009) Association between endogenous secretory RAGE, inflammatory markers, and 
arterial stiffness. Int J Cardiol 132: 96-101. 
15. Del Turco S, Navarra T, Gastaldelli A, Basta G (2011) Protective role of adiponectin on 
endothelial dysfunction induced by AGEs: a clinical and experimental approach. 
Microvasc Res  82: 73-76. 
16. Semba RD, Arab L., Sun K, Nicklett EJ, Ferrucci L (2011) Fat mass is inversely 
associated with serum carboxymethyl-lysine, and advanced glycation end product, in 
adults.  J Nutr 141: 1726-1730. 
17. Derosa G, D’Angelo A, Mugellini A, Pesce RM, Tegerl E, Maffioli P (2012) Evaluation 
of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-
year study. Curr Med Res Opin 28(9):1935-1945. 
18. Choi KM, Han KA, Ann HJ, Hwang SY, Hong HE, Choi HY, Yang SJ, Yoo HJ, Baik 
SH, Choi DS, Min KW (2012) Effects of exercise on sRAGE levels and cardiometabolic 
risk factors in patients with type 2 diabetes: a randomized-controlled trial. J Clin 
Endocrin Metab Jul 26. (e-pub ahead of print). 
19. Basta G, Turco SD, Navarra T, Mazzarisi A, Cocci F, Coceani M, Bianchi M, Schleuter 
M, Maraccini P (2012)  Inverse association between circulating levels of sRAGE and 
coronary plaque burden. J Atheroscler Thromb Jul 6. (e-pub ahead of print). 
43 
 
 
20. Maeda S, Matsui T, Matsui T, Takeucchi M, Yamagishi S (2011) Pigment epithelium-
derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced 
suppression of adiponectin mRNA levels in adipocytes by inhibiting NADPH oxidase-
mediated oxidative stress generation. Int J Cardiol 152(3): 408-410.  
21. Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, Lyons TJ, 
Jenkins AJ, Baynes JW, Thorpe SR (1997) Carboboxyethylethanolamine, a biomarker of 
phospholipid modification during the Maillard reaction in vivo. J Biol Chem 272: 17453-
17479. 
22. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. 
Nature 414: 813-820 
23. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H (2008) Oral glycotoxins 
determine the effects of calorie restriction on oxidant stress, age-related diseases, and 
lifespan. Am J Pathology 173(2): 327-336 
 
44 
 
Table 4.1. Pearson’s Correlations: Biochemical Parameters and Indicators of Adiposity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p≤0.05; 
**p<0.01 
 Weight Waist BMI sRAGE HMW 
Adiponectin 
Waist: r 
Sig 
N 
0.830 
0.000** 
72 
    
BMI: r 
Sig 
N 
0.806 
0.000** 
72 
0.790 
0.000** 
72 
   
sRAGE: r 
Sig 
N 
-0.364 
0.002** 
72 
-0.334 
0.004** 
72 
-0.364 
0.002** 
72 
  
HMWAdip
o: r 
Sig  
N 
-0.518 
0.002** 
34 
-0.541 
0.001** 
34 
-0.479 
0.005** 
34 
0.416 
0.016* 
34 
 
CML:r 
Sig 
N 
-0.169 
0.164 
69 
-0.169 
0.164 
69 
-0.038 
0.754 
69 
0.237 
0.050* 
69 
-0.175 
0.337 
32 
45 
 
 
 
Figure 4.1. Relationship Between BMI Classification (Normal; Overweight; Obese) and sRAGE 
(expressed in pcg/ml). * 
*Data expressed as means +/- SD. 
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CHAPTER V  
ADVANCED GLYCATION END PRODUCTS, INFLAMMATION, AND CHRONIC 
METABOLIC DISEASES: LINKS IN A CHAIN? 
 A Paper Accepted for Publication in Critical Reviews Food and Nutrition Science 
Kathleen E. Davis 
ABSTRACT 
Advanced glycation end products (AGEs) are a diverse group of compounds produced 
when reducing sugars react with proteins or other compounds to form glycosylated molecules. 
AGEs may form endogenously, and glycation of molecules may negatively affect their function. 
AGEs may also be consumed in food form with dietary AGEs reported to be particularly high in 
foods treated with high heat: baked, broiled, grilled, and fried foods. Whether dietary AGEs are 
absorbed in significant quantities and whether they are harmful if absorbed is a question under 
current debate. The American Diabetes Association makes no recommendation regarding 
avoidance of these foods, but many researchers are concerned that they may be pro-inflammatory 
and way worsen cardiac function, kidney function, diabetes and its complications and may even 
contribute to obesity. 
INTRODUCTION 
Advanced glycation end products (AGEs) are a diverse group of compounds formed 
when glucose or other reducing sugars react with amine groups linked to proteins, nucleotide 
bases or fatty acids, forming glycosylated products. Some of these products include 
carboyxmethyllysine (CML), hydroimidazolone, pentosidine, glucosepane, and others (Semba, 
Nicklett 2010).  
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The Maillard browning reaction in foods, a necessary precursor to the formation of 
AGEs, was first described by Louis Camille Maillard in 1912, and for many, the Maillard 
reaction is most familiar as something belonging to the realm of food science, affecting the color, 
flavor, and acceptability of cooked food. However, increasingly this reaction and the reactions 
which may follow it are being investigated for their role in negative physiological effects in the 
body.   
The first indirect support for health implications of non-enzymatically glycated proteins 
came from observations of increased formation of hemoglobin A1c in parallel with poor glucose 
control in persons with diabetes (Trivelli 1971).  Hemoglobin A1c is an Amadori product, a 
ketoamine formed as the ultimate product of a reaction between glucose and the free amine group 
on the valine residue of the hemoglobin beta chain (Saudek 2006). It is not an AGE, but it is the 
standard for determining adequacy of blood glucose control in diabetes today (Saudek 2006). It is 
used as an indicator of the 3-4 month average of blood glucose values, with goals for patients 
with diabetes set at a hemoglobinA1c of less than 7% or 6.5% (Saudek 2006). While hemoglobin 
A1c is not an AGE, this research became an important springboard for future AGE research. The 
implications of AGEs as possible pro-inflammatory compounds gained further steam and 
legitimacy when the receptor for AGEs (RAGE) was cloned in 1992 (Schmidt 1992; Semba, 
Nicklett 2010). Other receptors for AGE have since been identified.  
WHAT ARE AGEs? 
The Maillard browning reaction, which yields a yellowish-brown colored product, 
precedes the formation of AGEs.  In this process, a reducing sugar and amine group react, non-
enzymatically forming a Schiff base, which may then form more stable Amadori products (Wu 
2011).  The first part of this reaction is reversible, so AGEs may not result from the initial 
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browning reaction; however, the Amadori products, once formed, lead inexorably to the 
formation of AGEs.  AGEs are produced when the Amadori products are further modified by 
dehydration, oxidation, rearrangement or other reactions, leading to the formation of cross linked 
or non-cross linked derivatives of sugar and other molecules (Barlovic 2011; Wu 2011). See 
Figure 1 (Sell 2012) for a detailed look at how AGEs are formed.  
Although AGEs include pyrraline, pentosidine, carboxymethyllysine, glucosepane and 
some 16 plus other structures (Ames 2007), hemoglobin A1c, though an Amadori product, is not 
an AGE.  AGEs are found both in food and within the body.  Among cross-linked AGEs are 
crossline, 2-(2-furoyl)-4(5)-(2-furanyl)-1H imidazole (FFI), glyoxal-lysine dimer (GOLD), 
methyl-glyoxal-lysine dimer (MOLD) and others  (Wu 2011). Non cross-linked AGEs include 
CML, carboxyethyllysine (CEL), pyrraline, and argpyrimidine (Wu 2011).  
The substances formed when reducing sugars interact with substances containing a free 
amino acid group may be called pre-AGEs. In addition, sugars in the body or in food may be 
oxidized to form dicarbonyls such as glyoxal (GO) and methylglyoxal (MG).  GO and MG are 
not themselves AGEs and may have other fates, but are thought to have strong AGE potential and 
the ability to form cross-linked AGEs via reaction with arginine residues. The product of this 
reaction is the AGE hydroimidazolone. In addition, GO and MG may impact formation of 
reactive oxygen species.  (Ames 2007; Wu 2012) 
MEASURING AGEs 
Although several procedures are available for measuring AGEs, neither a universally 
accepted technique nor normative values have been established. Immunochemical and 
instrumental methods are most often employed to measure AGEs. Immunochemical methods 
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(enzyme linked immunosorbent assay or ELISA)  have the advantage of requiring less expensive 
equipment in order to begin quantification, but studies employing these methods have been 
criticized for being non-specific due to the nature of the antibodies employed and also for 
reporting AGE in ―Units‖ per average portion (Goldberg 2004; Uribarri 2010; Ames 2008). 
Instrumental methods used to quantify AGEs in food have included liquid chromatography 
combined with fluorescence detection or mass spectrometry (HPLC, UPLC) or in some cases gas 
spectrophotometry (GC) (Ames 2008; Birlouez-Aragon 2004; Hull 2012; Assar 2009; Delgado-
Andrade 2006, 2007; Drusch 1998; Yaacoub 2008). Instrumental methods are usually accurate, 
repeatable and express AGEs in milligrams (mg) per kilogram (kg) of protein, mg/100 grams (g) 
of food or mg/average portion size.  
The problem in comparing published AGEs data are multiple. These include method used 
for quantification (instrumental versus ELISA) and antibody-dependent differences in ELISA 
assays that may measure different AGEs products. In addition, despite the identification of at 
least 20 AGE structures, CML has been most often reported in the literature as a measure of 
AGEs (Semba, Nicklett 2010). The use of CML as a proxy for measuring AGEs is based on early 
studies indicating that CML levels correlate directly with levels of other protein or lipid AGEs 
(Cai 2008; Brownlee 2001; Requena 1997).  However, much remains to be understood about the 
physiologic significance of the large AGEs family of structures and which should be measured as 
a marker of AGEs load.  
AGEs have multiple receptors including RAGE, AGERs 1, 3, and CD35 receptors, which 
will be discussed further in the section on ―Metabolism and Pathophysiology‖. In addition, given 
the discovery that RAGE has multiple ligands and that during an inflammatory response, the 
binding of the ligand to RAGE leads to increased expression of RAGE (Fritz 2011), it is 
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reasonable to ask whether each ligand has an equal affinity for RAGE and whether CML is the 
most important ligand in promoting inflammation. The ligands for RAGE identified so far include 
AGEs, S100 proteins (a protein family consisting of 25 members, which have metal ion binding 
properties), amyloid beta and amyloid fibrils, high mobility group box 1 protein (HMGB1) and 
beta2-integrin macrophage-1 antigen (Fritz, 2011). RAGE is classified as a ―pattern recognition 
receptor‖ because of its ability to allow binding by a diverse group of ligands (Ramasamy 2010).  
Questions remain regarding whether all ligands for RAGE have been identified, which are most 
important, and how they may interact with or compete for the RAGE receptor.  
Some progress is being made in this regard. A recent study attempted to use UPLC with 
mass spectrometry (UPLC-MS) to analyze the glycating activity of AGE-precursors.  This study 
identified five AGE structures which did not match any known product, but it also confirmed that 
CML and CEL were abundant AGEs formed from well-known AGE precursors such as MG GO 
and glucosone (Mittelmaier 2011). 
Another problem in the AGE literature is that measured AGEs in foods vary based on the 
quantification method used. Roast chicken breast in which AGEs were quantified using ELISA is 
reported to have 5,245 kU of AGE per 90 g serving (Goldberg 2004; Uribarri 2010). Using 
UPLC-MS, a 90 g serving is reported to have 0.4 mg/ serving (Hull 2012).  This compares to 825 
kU of AGE per 90 g serving of canned salmon (ELISA) and 6.2 mg/90 g (UPLC) (Hull 2012; 
Goldberg 2004).  Thus, according to ELISA measurements, broiled chicken is high in CML 
whereas canned salmon is low (Uribarri 2010). Conversely, according to UPLC measurements, 
canned salmon contains high levels whereas broiled chicken contains low levels (Hull 2012). 
To further illustrate the point, Kellogg’s Corn Flakes have either 70 kU of AGE per 30 
gram serving (ELISA) or 1.6 mg per 30 gram serving size (UPLC). Again, this equates to a very 
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low measurement for corn flakes compared to most of the foods in the ELISA-based food AGE 
database and a high measurement of AGE compared to most foods in the UPLC-based food AGE 
database, exceeding that of braised steak, battered cod and pork sausage but not of whole milk 
yogurt (Goldberg 2004; Uribarri 2010; Hull 2012). This picture is confusing and needs to be 
rectified. A recent study comparing the use of UPLC, ELISA and another method to determine 
the CML content of known samples of glycated bovine serum albumin found good correlation 
between the various methods; however the r
2
 value was just 0.75 for UPLC and ELISA. (Srey 
2010) Foods were not tested in this study, thus more work needs to be done to evaluate whether 
these methods are equally valid in testing CML content of a variety of foods.  
Measurement of serum and plasma AGEs in human subjects is less difficult and less 
controversial. CML is the favorite AGE for measurement, and a few kits are available. However, 
reporting of data is not in standard units.  
Serum AGEs have been reported in the range of 8.5 ± 0.9 Units/ml in men less than age 
45, 9.9 ± 1.5 in men older than 60, 7.9 ± 0.7 in women less than age 45 and 10.7 ± 1.1 in women  
older than 60 in a study of 172 healthy individuals (Uribarri, Negrean 2007). In a group of 60 
healthy women and women with polycystic ovarian syndrome (PCOS), healthy women had AGE 
levels of 5.85 ± 0.89 Units (U)/ml, and women with PCOS had higher levels: 8.7 ± 1.65 U/ml 
(Diamanti-Kandarakis 2009).  Yamagishi (2006), using a different CML antibody for ELISA, has 
reported serum CML concentrations of 4.1 ± 0.7 U/ml in men and 4.1 ± 0.9 U/ml among 184 
healthy participants. 
In the Italian In-CHIANTI study CML was reported in nanograms (ng)/ml, and 
participants with the slowest walking speeds had reported plasma CML levels of 375 ng/ml 
compared to 343 ng/ml for those with the fastest speeds (Semba, Bandanelli 2010). Using the 
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same assay, a separate study reported CML levels of 344 ng/ml for healthy participants and 390 
ng/ml for participants with chronic kidney disease (Semba 2009). Reporting values in standard 
units might help establish norms for AGEs and make it more useful as a biomarker for 
inflammation.  
ENDOGENOUS AGEs 
 
AGEs have both endogenous and dietary origins and are thought to contribute to 
oxidative stress within the body. Endogenous AGE formation occurs slowly but may be up-
regulated in conditions of metabolic stress such as sepsis and insulin resistance and in disease 
states such as diabetes and chronic kidney disease. Hyperglycemia may also lead to up-regulation 
of pathways other than glycolysis including the polyol pathway, which increases AGE 
production. Activation of protein kinase C could also stimulate the hexosamine pathway, 
increasing endogenous AGE. Furthermore, an increase in reactive dicarbonyls and reduced 
detoxification by the glyoxalase system is thought to lead to a state of carbonyl stress, which may 
increase endogenous AGEs. (Barlovic 2011) 
EXOGENOUS AGEs  
Because AGEs are glycated molecules, one might expect that foods rich in carbohydrates 
would be important dietary sources. In fact exogenous AGE consumption typically increases in 
high fat diets and when high temperature cooking methods such as deep-frying, broiling, roasting 
and grilling are used. This is particularly true for high protein products (Semba, Nicklett 2010). 
However, CML tables produced by Hull, which employ UPLC, also indicate the presence of 
increased AGEs in high carbohydrate foods (Hull 2012).  
Whether dietary AGEs contribute significantly to deleterious health effects is a topic of 
active investigation. They were once considered insignificant due to early research showing that 
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small amounts of dietary AGE were absorbed in rats, primarily in the large intestine, with only 
about 1.5% being found in the liver after absorption (Sgarbieri 1973). A 1997 study in humans 
found only about 10% of dietary AGEs were absorbed. However, in this study, in persons with 
normal kidney function, approximately 30% of ingested AGEs were found to be excreted in the 
urine; whereas, for those with impaired kidney function, as estimated by glomerular filtration 
rate, as little as five percent of ingested AGE was excreted in the urine. A high AGE diet was also 
found to result in significant elevations in serum AGE post feeding despite low absorption 
(Koschinsky 1997).  
In an in vitro experimental model assessing diet derived AGEs’ effects on glutathione 
(GSH) and GSH peroxidase (GPx) (indicators of oxidative stress), on human umbilical vein 
endothelial cells (HUVECs), it was reported that AGEs depleted GSH and increased GPx activity 
(Cai 2002). The authors concluded that prior to absorption, food-derived AGEs contain carbonyl 
species, which may induce oxidative damage.   
The larger studies which have attempted to create CML food databases are ELISA based: 
Goldberg 2004 and the follow-up, Uribarri 2010. A limitation of the Goldberg study was that the 
methods section did not describe whether multiple samples/trials were performed in order to 
determine AGE. AGEs were reported to be lowest in carbohydrate foods with the lowest levels 
within this group being found in milk, followed by vegetables and fruits. Broiled beef, and 
chicken, oils heated to high levels and roasted nuts were among the foods highest in CML. These 
data have been criticized in part because of the finding that oils were found to be high in CML. 
Because oils should contain no lysine, some question how they could also be rich in CML.  
However in a later publication, the researchers hypothesized that extraction and purification 
procedures accounted for this finding (Uribarri 2010). Elsewhere the same group of researchers 
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analyzed food records from healthy participants and found mean daily AGE intake to be about 
14,780 +/- 680 kU AGE (Uribarri 2007; Uribarri 2010) compared to an earlier report of average 
intakes of 16,000 ± 5000 kU AGE (Goldberg 2004).   
A study of a variety of common foods published in 2009 found levels of CML to vary 
from as low as 0.3 mg/kg of raw milk and 0.35 mg/kg of skim milk to as high as 46.1 mg/kg of 
whole meal bread crust (compared to just 4.45 mg/kg of bread crumb) (Assar 2009). Commercial 
breakfast cereals and ice creams also appear to be sources of AGE (Delgado-Andrade 2006; 
Drusch 1999).  An evaluation of a variety of processing methods for nuts and seeds found that 
CML production was increased by roasting methods. Thus consumption of cooked foods 
compared to raw foods increases AGE ingestion (Yaacoub 2008).  
Intermediate products or AGE-forming metabolites  include methylglyoxl (MG) and 
glyoxal (GO). In a study evaluating the MG and GO content of soft drinks the trend was for 
products containing high fructose corn syrup to be relatively high in MG whereas diet drinks 
were not (Tan 2008). However, another analysis of AGEs in soft drinks employing ELISA found 
that AGE levels in soft drinks did not correlate with sugar content as long as protein and heat 
were not present. In fact drinks with caramel additives such as Coke Classic or Diet Coke were 
found to contain 8500 and 9500 units/cup compared to 475 units/cup in Sprite, 600 in orange 
juice and around 2000 in coffee and tea (Koschinsky 1997).  
METABOLISM AND PATHOPHYSIOLOGY OF AGES 
Enzymatic Disposal and Mechanistic Action 
The body has a number of ways for degrading AGEs including the degradative enzymes  
glyoxalase I and II, which degrade and detoxify the pre-AGEs MG and GO along with aldose 
reductase and carbonyl reductase, which  prevent formation of AGEs. Circulating proteins such 
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as lysozyme, defensins and lactoferrin may also bind AGEs in circulation, preventing them from 
binding elsewhere within the cells (Vlassara 2008). However, degradation may not always be 
rapid enough to keep up with production as in cases of hyperglycemia or severe oxidative stress. 
In addition, in kidney disease the body appears to decrease its capacity to degrade and excrete 
AGE to sufficient levels (Koschinsky 1997). 
There are also two types of cell surface AGE receptors, one which binds AGE and 
initiates cell activation and another which binds, internalizes and degrades AGE. The RAGE 
receptor for AGE is thought to initiate oxidative stress whereas the AGERs 1, 3, and CD35 
receptors help to mediate degradation of AGE (Vlassara 2008). Damage caused by AGEs is 
thought to result from activation of nuclear factor kappa beta (NF-ĸβ) which leads to up-
regulation of genes for cytokines, growth factors and cell adhesion molecules (Kalousova 2005).  
Brownlee (2001) described ways in which AGEs may damage target cells leading to 
diabetic complications. Three primary means of damage may be: modification of cellular proteins 
by glycation leading to loss of function, extracellular proteins or other molecules modified by 
AGE might interact differently with their receptors, and receptor-mediated AGE oxidative 
processes may also cause cellular damage.   
In fact most mechanistic explanations of how AGE may cause oxidative damage suggest 
that AGEs exert influence via receptors. RAGE receptors may be expressed on the surface of a 
variety of cells including neurons, smooth muscle cell monocytes, endothelial cells, fibroblasts 
and more (Kalousova 2005).  The RAGE receptor may then activate signal transduction pathways 
including extracellular signal-related kinase (ERK), mitogen activated protein kinase (p38 
MAPK
), 
c-jun N terminal kinases (JNK) and NF-ĸβ.  Thus, transcription of genes may be stimulated 
which will up-regulate production of growth factors such as tumor necrosis factor (TNF-α), inter-
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leukin 1 (IL-1) and insulin like growth factor-1 (IGF-1) and adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecules (VCAM-1). In 
addition, it is suggested that DNA may undergo glycation. Thus, AGE modification of DNA 
could affect regulatory and epigenetic processes at the DNA level (Ramasamy 2005). In addition, 
RAGE may be differentially spliced forming endogenous secretory RAGE (esRAGE). RAGE 
may also be cleaved from the cellular surface. The pool of both differentially-spliced and cleaved 
RAGE is known as soluble RAGE (sRAGE) which may act as a decoy receptor aiding in 
secretion of AGE (Barlovic 2011).   
Pharmacokinetics 
As discussed earlier under exogenous AGEs, one major study has attempted to answer 
questions regarding the pharmacokinetics of AGEs. In it, 43 subjects, (38 male and 5 female) 
including 38 with diabetes and 5 healthy participants were given high AGE test meals, which was 
followed by 48 hours of post meal evaluation. Urine samples were collected 48 hours after the 
test meal.  Changes in serum and urine AGE kinetics were calculated and plotted as the area 
under the curve (AUC) (Koschinsky 1997). Participants consumed differing quantities of AGE, 
but there was a correlation between the amount consumed and the area under the curve (elevation 
in serum AGE). Only 10% of the AGEs ingested were accounted for in serum in this study. Only 
one-third of the AGEs detected in serum were detected in the urine. Thus, what happened to the 
other two-thirds was not explained by this study. (Koschinsky 1997)  
Other studies related to pharmacokinetics of CML have primarily been done in animals 
(Somoza 2006; Tessier 2012) with a few exceptions. Birlouez-Aragon et. al. reported higher 
urinary excretion of CML in participants fed a high AGE diet; however labeled products were not 
fed, so the relationship was correlational only (Birlouez Aragon 2010).  
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PATHOPHYSIOLOGY 
 
Healthy Individuals 
There is a paucity of human studies involving healthy adults and AGE. Uribarri and co-
investigators correlated calculated dietary AGE content and serum AGE in 90 healthy subjects 
and found increases in CRP with both dietary AGE and serum AGE (Uribarri 2005). In five 
participants taken from this group of 90, short term dietary AGE restriction decreased serum 
AGE levels by 30-40 percent. Based on this single study it is possible to say only that dietary 
AGE may significantly impact AGE levels even in healthy individuals in spite of low absorption.  
Birlouez-Aragon also conducted an AGE feeding study involving healthy individuals 
with average BMI of 21.8 kg/m
2 
(range 18-26.9) and found that after four weeks of feeding a 
steamed diet (low in CML) versus a conventional diet (comparatively higher in CML), 
participants on the steamed diet had 5% lower plasma total cholesterol, 10% lower HDL, and 9% 
lower triglycerides (Birlouez Aragon 2010). However, it should be pointed out that the 
participants consuming the steamed diet (who were fed ab lib) consumed significantly less 
energy, significantly less total fat, and more vitamin C than the participants consuming the 
standard diet, thus this data is somewhat confounded.  
Obesity 
AGEs may play a more prominent role in the health of obese individuals. The literature 
suggests that AGEs are involved in inflammatory processes, which are often increased in obesity 
(Ramasamy 2005; Brownlee 2001).  The extent to which elevated circulating AGEs are the cause 
or symptom of disease and how AGEs, RAGE and sRAGE may be influenced by factors such as 
body fatness and lifestyle is not clear. 
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In several studies in older adults, fatness and sRAGE appear to be linked. Koyama et. al. 
reported an inverse correlation of components of the metabolic syndrome with sRAGE. 
Components demonstrating this inverse relationship included body mass index, TG, HbA1c and 
insulin resistance, which were all inversely linked with sRAGE in both diabetic and non-diabetic 
participants (Koyama 2005). Another Japanese group also found sRAGE to be inversely 
correlated with BMI, waist circumference, AGE intake and alcohol intake (Yamagishi 2006). 
Norata et. al. also reported that sRAGE was inversely correlated with BMI, waist/hip 
circumference and fasting glucose with a positive correlation to apolipoprotein A-1 (Norata 
2009). Thus, the link between sRAGE and fatness in older adults seems to be established based 
on several studies done in separate populations.  
In studies relating AGEs to BMI, the correlation is usually direct. Semba et. al. used 
DEXA to establish body fatness and found that total fat mass, truncal fat mass and appendicular 
fat mass were each correlated with serum CML when controlled for age, sex, BMI, blood 
pressure, TG, HDL and renal function. This suggests that body fat affects CML and possibly 
other AGEs perhaps because AGEs may be stored in fatty tissue (Semba 2011).  Diamanti-
Kandarakis et. al. also found a correlation between AGEs and BMI (Diamanti-Kandarakis 2009), 
as did a study by Yamagishi et. al. (Yamagishi 2006). However, in a study of obese children and 
adolescents, levels of AGEs were actually lower in the obese children compared to controls 
(Sebekova 2009). Given more limited data in this area, the link between AGEs and fatness is 
suggestive but not confirmed. 
Finally Yamagishi et. al. identified a correlation between sRAGE and AGE. However, 
they found a positive correlation between the two. This seems counter-intuitive given research 
suggesting that AGEs increase with increasing BMI whereas the link is opposite for sRAGE. This 
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group of researchers hypothesized that sRAGE may reflect tissue RAGE expression and that 
sRAGE may increase along with AGE in order to mount a counter-defense (Yamagishi 2006).   
In the only study of weight loss and AGEs in obese subjects, Gugliucci et. al. treated 37 
Japanese participants (30 females, 7 males) with a low calorie diet (1200 kcals/5020 KJ daily) for 
2 months. Participants reduced their BMI, waist circumference and TG but also reduced serum 
AGEs by 7.2%. Whether the reduction in AGEs was due to decreased fat mass, a reduction in 
glycation due to caloric restriction, or a decreased intake of dietary AGEs was not assessed. 
(Gugliucci 2009) 
Diabetes and Diabetes-Related Cardiovascular Disease 
The link between serum AGE  and inflammatory stress in diabetes is comparatively 
strong. In a study by Tan (2004), serum AGEs were significantly increased in persons with 
diabetes, and CRP was highly correlated with AGEs.  Regression analysis demonstrated that 
BMI, interleukin-6 (IL-6) and CRP were determinants of AGEs (Tan 2004). An earlier study also 
by Tan found significant increases in serum AGE in persons with diabetes and found AGEs to be 
correlated with endothelium-dependent vasodilation (Tan 2002). In addition, dietary AGEs may 
result in prolonged increases in serum AGEs in persons with diabetes. Koschinsky et. al. 
evaluated the effect of a single meal containing egg white cooked with or without fructose 
(with=AGE; without=control) in 38 participants with type 2 diabetes. This study first showed that 
not only was serum AGE increased with dietary consumption but also that AGE levels remained 
elevated in persons with both diabetes and severe renal disease for more than 48 hours after 
ingestion (Koschinsky 1997). 
Studies involving diabetic complications related to AGEs have shown that AGEs are 
increased in vessels of the retina and in renal glomeruli in persons with diabetes (Brownlee 2001). 
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Animal based studies have also demonstrated fewer diabetic complications, especially 
microvascular complications, in mice fed reduced AGE diets. Follow-up multicenter trials of an 
AGE inhibitor (aminoguanidine) demonstrated reduced diabetic retinopathy (Brownlee 2001). 
While this drug did not progress to clinical trials, other potential AGE drugs include AGE 
breakers such as ALT 711 (Friedja 2012). 
Studies relating to macrovascular complications of diabetes also indicate a role for AGEs. 
Patients with diabetes randomized to a low AGE diet were found to have less glycated serum 
LDL and oxidized serum LDL compared to those fed the standard diet (Cai 2002).  In the 
Diabetes Control and Complications Trial, oxidized and glycated LDL were found to correlate 
well with duration of diabetes, BMI, and lipid levels (Lopes-Virella 2011). Serum AGEs were 
found to correlate with triglyceride levels in a study of diabetes-related cardiovascular disease, 
and those with the highest AGEs had the most adverse lipid profiles (Chang 2011).  
While mechanisms for damage in diabetes have usually been related to signaling and 
inflammatory processes as previously described, one study involving both cells and mice with 
diabetes found that AGEs were acutely toxic to pancreatic beta cells, causing loss of manganese 
superoxide dismutase (SOD) and increased glucose uptake. In addition, rats fed high AGE diets 
had progressive insulin secretory defects and beta cell death (Coughlan 2011).   
 Studies which have attempted to manipulate the diet of persons with diabetes to include 
fewer AGEs have demonstrated positive results. Negrean et. al. fed persons with type 2 diabetes  
isocaloric diets with identical ingredients but which were prepared using different cooking 
methods in order to obtain high and low AGE test meals followed by measurement of endothelial 
function using flow-mediated dilation (FMD) and Laser-Doppler flowometry. FMD was found to 
decrease significantly more after the high AGE meal (a decrease which was 1.5 times greater than 
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the low AGE meal change). AGE did not affect glucose, triacylglycerol levels or insulin. No 
significant changes in inflammatory markers were found (Negrean 2007, Stirban 2008). 
 A separate report of a similar study by the same group of researchers demonstrated 
increased serum AGE and increased glycated LDL in 11 diabetic subjects fed a high AGE diet in 
a two-week crossover study. Thirteen participants in a longer 6 week low or high AGE 
intervention also were noted to have increased glycated LDL while on the high AGE diet 
(Vlassara 2002).  
In feeding stable diabetic participants and healthy participants an oral AGE challenge 
beverage with no carbohydrate or lipid, Uribarri et. al, found  that maximal arterial dilation after 
ischemia decreased significantly with no changes in glucose or VCAM-1. This decrease in FMD 
is thought to be indicative of impaired endothelial function resulting from the AGE bolus 
(Uribarri, Negrean 2007).  
Each study seems to indicate a possible positive impact of a low-AGE diet on diabetes-
related cardiovascular diseases. However, even though many studies in the field of diabetes have 
been done with regard to AGEs, the evidence is regarded as insufficient to warrant changes in 
dietary advice to persons with diabetes (Diabetes Care 2012). 
Kidney Disease 
AGEs are thought by some to damage nephrons by altering the structure and function of 
proteins and by injuring cells (Uribarri 2006) due to changes in cellular adhesion molecules and 
inhibition of processes leading to the production of type IV collagen and laminin fibers (Uribarri 
2006). Serum AGEs correlate with inflammatory markers and are inversely associated with 
creatinine clearance (Vlassara 2009). Proof that AGEs damage renal function is currently lacking, 
but suggestive data is available.  
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The impact of dietary AGEs on kidney function has been evaluated in overweight and 
obese adult males randomized to two weeks on a low and high AGE diet (Harcourt 2011). In this 
study fat was held constant at 30% with AGE being the primary variable, and AGE was 
calculated based on the Goldberg values (2004). The researchers found that albumin to creatinine 
ratios were improved following the low AGE diet. In addition plasma AGE increased following 
high AGE consumption. Some drawbacks to this study design include likely differences in type 
of fat in the study due to the dietary approach used.  
 In a large study of older community-dwelling adults, CML was associated with chronic 
kidney disease and glomerular filtration rate (GFR), the primary indicator of CKD. This remained 
true at 3 and 6 year follow-up. While this study shows CML to possibly be a good indicator of 
renal function, it does not prove that dietary CML negatively impacts GFR (Semba 2009). 
Similarly in the Baltimore Longitudinal Study of Aging in which 750 adults were followed for 52 
years, serum CML was associated with CKD (p=0.003) and decreasing GFR (Semba, Fink 2010).  
Studies in animals have demonstrated that aminoguanidine (an AGE inhibitor) decreases 
kidney disease in aging rats (Vlassara 2009; Li 1996). In addition a life-long restriction of dietary 
AGEs in mice decreased kidney lesions in aging mice (Vlassara 2009; Cai 2008).  
However, Schwedler et. al. found that elevated serum AGEs were not related to mortality 
in patients on hemodialysis (HD). CML and AGE were definitely lower in healthy controls 
compared to those on HD, but mortality was not associated with CML (Schwedler 2002).  
A fairly scathing critique of the above literature in kidney disease and AGEs research was 
recently written by Piroddi et. al. This group of researchers measured CML in serum using 
chemiluminescent detection and immuno-blots and pentosidine using reverse-phase HPLC 
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analysis (Piroddi 2011).  CML and pentosidine  levels were increased in CKD and HD patients, 
but intake of CML was lower in participants with CKD or HD. Piroddi et. al. reported a negative 
correlation between CML intake and plasma CML and a positive correlation of CML and protein 
intake. They concluded that CML in the plasma does not correlate with dietary intake and should 
not be restricted in healthy individuals or those on HD. They also claimed that the CML epitope 
measured by the assay used by Vlassara, Semba and others at Mt. Sinai is present in low 
abundance in human serum and in food (Piroddi 2011). 
Cardiovascular Disease 
An animal model developed by Ueno and Koyama has sought to determine whether 
RAGE is linked to progression of atherosclerosis (Ueno 2010). Variations of RAGE and 
apolipoprotein E (ApeE) knockout mice were produced and randomly assigned to atherogenic 
diet and standard chow diet from 6 weeks to 20 weeks of age. The ApoE
-/-
RAGE
-/-
 mice fed with 
either diet had decreased plaques even though no differences in cholesterol or glucose were 
observed. The ApoE
-/-
RAGE
-/-
 mice also gained significantly less body weight despite no 
difference in food intake. Thus, it appears that mice deficient in RAGE have improved body 
fatness and less atherogenesis, an intriguing finding should it also be found to be true in humans. 
(Ueno 2010) 
Another group of researchers identified a decrease in leptin after high AGE feeding in 20 
in-patients with type 2 diabetes.  They also found decreases in adiponectin and increases in 
VCAM-1 and e-selectin (Stirban 2008). The same group did a separate study involving 13 
persons with type 2 diabetes and found that a high AGE test meal significantly impaired 
macrovascular FMD (Stirban 2006).  The findings in the animal study together with the studies 
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previously discussed with regard to cardiovascular disease related to diabetes (Cai 2002, Lopes-
Virella 2011, Chang 2011, Vlassara 2002, Negrean 2007, Stirban 2008), indicate a possible 
association between foods high in AGE and impacts on oxidized LDL, glycated LDL, and 
endothelial dysfunction, all indicators of atherogenesis.   
Population based studies have also indicated a possible role for AGEs in cardiovascular 
disease and mortality. Kilhovd et. al. determined in a Finnish population of persons with and 
without diabetes that increased serum AGE predicted total and cardiovascular disease-related 
mortality in women but not men (Kilhovd 1999, 2005, 2007). Similarly, Nin et. al. found plasma 
AGE (CML and pentosidine) to be linked to fatal and non-fatal cardiovascular disease in 339 
patients with type 1 diabetes (Nin 2011). Kiuchi et. al also identified that AGE levels increased 
with severity of cardiovascular disease in a Japanese population with diabetes (Kiuchi 2001). 
CONCLUSIONS 
 Much has yet to be done in AGEs research. We need to better understand the 
pharmacokinetics of AGEs. With so little being excreted in the urine or discovered deposited in 
tissues, what is the fate of the remainder of ingested AGEs? Are there important differences in the 
influence of AGEs in the body based on disease state and age? Do different AGEs interact with 
receptors differently with different results? More fundamentally, which AGE is the most 
important to measure, and can we decide as a scientific community on an ideal way of 
quantifying AGE in the body and in foods? 
 Another incomplete area of research includes the interaction between dietary 
macronutrient composition and serum AGE and sRAGE. Much has been made of the importance 
of low fat diet in lowering risk of cardiovascular disease. However, cooking methods 
recommended for lowering fat intake such as broiling, grilling and roasting tend to increase 
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concentrations of AGEs in foods. Current research suggests that AGEs increase oxidative and 
carbonyl stress, decrease cardiovascular endothelial dysfunction, and contribute to cellular 
damage related to diabetes and chronic kidney disease. In addition increased body fat and body 
weight are associated with higher levels of AGE and decreased levels of an important receptor for 
AGE (sRAGE). Since low-fat diet is often recommended for weight control in obese and 
overweight persons, it is important to determine to what extent a low fat diet using these 
commonly advised cooking methods may contribute to AGE load and whether such a low-fat diet 
may negatively affect inflammatory cytokines thought to be influenced by AGE.  
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Figure 5.1.* Formation of AGEs.  
*This figure is provided with permission of  S. Karger AG, Basel.  DR Sell and VM Monnier. 
Gerontology 2012.  
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CHAPTER VI   
 
HIGH-FAT, HIGH-ADVANCED GLYCATION END PRODUCTS DIET PROMOTES RISE 
IN SERUM N-EPSILON-CARBOXYMETHYLLYSINE 
A Paper to be Submitted for Publication   
ABSTRACT 
 The Western diet, which is high in simple carbohydrates and fat and low in fruits and 
vegetables, favors inflammation. However, the cause of this inflammation is controversial. Some 
research suggests that advanced glycation end products (AGEs), compounds produced when 
foods are heat treated at high temperatures may play a role. The purpose of this study was to 
determine whether macronutrient content (low-fat versus high fat diet) influences an indicator of 
AGEs: n-epsilon carboxy-methyl-lysine (CML) in the presence of a high AGE diet and whether 
the soluble receptor for AGEs (sRAGE) increases in response to a dietary AGE load. A pattern 
toward decrease in CML was found following consumption of a low-fat high AGE diet (p=0.12), 
and a pattern indicative of a rise in CML occurred following consumption of a high fat high AGE 
diet (p=0.15). The mean change in CML between the two diets approached, but did not reach 
significance (p=0.08).  sRAGE decreased in the hours after consumption of either high AGE meal 
(p=0.01). CRP and adiponectin were not affected by either test diet. These findings suggest that 
dietary AGE may not be very important in influencing inflammation or even serum CML in 
healthy adults without diabetes.  
INTRODUCTION 
 Western diet as it exists today favors inflammation and development of chronic diseases. 
Theories for the mechanism behind this observational finding include dietary imbalance of n-3 
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and n-6 fatty acids, consumption of high fat diet, inadequate intake of micronutrients and plant 
foods, excessive intake of refined or processed foods, and an imbalance in consumption of dietary 
acid and base (Cordain 2005). A less well known theory purports that cooking foods produces 
advanced glycation end products (AGEs),  compounds formed when sugars react with amino 
acids or other substances forming glycosylated molecules,  which are thought to favor oxidative 
stress when absorbed (Kalousova 2005; Vlassara 2011; Semba 2010, Barlovic 2011).  AGEs 
include pentosidine, n-epsilon-carboyxmethyllysine (CML), hydroimidazolone,  furosine, 
glucosepane, and many others. CML is the  most widely studied and is regarded as a good proxy 
measurement of AGE load in the body based on early studies (Cai 2008; Brownlee 2001; 
Requena 1997).  
Advanced glycation end products are produced very slowly within biological systems as 
blood glucose interacts with body proteins, but AGEs may also enter the body via dietary 
consumption, although only about 10% of dietary AGEs are absorbed (Sgarbieri 1973, 
Koschinsky 1997).  AGEs may increase oxidative stress via affinity for the receptor for AGE 
(RAGE), which initiates a cascade of events leading to decreased cardiovascular endothelial 
dysfunction and possible diabetic complications (Vlassara 2011). The soluble receptor for AGE 
(sRAGE) is thought to act as a decoy receptor, aiding the body removal AGEs (Raucci 2008; 
Kalea 2011).  
Several studies in food have demonstrated that dietary AGEs are  present in high 
concentrations in foods exposed to high temperature cooking methods, such as deep-frying, 
broiling, roasting, baking and grilling (Uribarri 2010). Additionally, foods that are high in protein 
and high in fat which are cooked using these methods tend to be particularly high in AGEs 
(Semba 2010). However, there is little consensus about appropriate measurement techniques for 
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quantifying AGE in foods and whether endogenous or dietary AGE found in a heat-processed 
Western diet may negatively impact inflammation (Ames 2008, Delgado-Andrade 2007, Drusch 
1999, Assar 2009, Vlassara 2011). Despite low levels of absorption, several studies have found 
decreased serum CML in participants (both human and animal) following reduced AGE diets 
(Koschinsky 1997, Cai 2002, Vlassara 2002, Uribarri 2005, Sandu 2005, Diamani-Kandarakis 
2006, Negrean 2007, Stirban 2008, Cai 2008, Uribarri 2007, Vlassara 2009, Harcourt 2011, Uribarri 
2011). In addition, a study by Tan et. al. (2004) found a correlation between dietary AGEs and C-
reactive protein (CRP), a prominent indicator of inflammation. However, no study has been done to 
compare the effect of consumption of a high-fat diet versus a low-fat diet when both are elevated in 
AGEs on serum CML and sRAGE. Currently, the effect of dietary AGE on serum AGE is not clear 
since the publication of a study by Semba et. al. in early 2012 which found no relationship 
between dietary records detailing AGE intake and serum AGE. 
 Current research suggests that AGEs increase oxidative and carbonyl stress, which may 
cause endothelial dysfunction, and contribute to cellular damage related to diabetes and chronic 
kidney disease. Additionally, increased body fat and body weight are associated with higher 
levels of AGE and decreased levels of an important receptor for AGE (sRAGE). Since low fat 
diet is often recommended for weight control in obese and overweight persons, it is important to 
determine whether a low fat diet prepared using cooking methods such as baking, broiling, 
roasting, and toasting contributes to AGE load and negatively affects inflammatory cytokines 
thought to be influenced by AGE.  
  The purpose of this study was to determine if a low fat diet cooked using high heat 
methods has equivalent effects on serum AGE and inflammatory cytokines when compared to a 
high fat diet cooked using similar high heat cooking methods.    
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METHODS 
 
 This study was approved by the Texas Woman’s University Institutional Review Board’s 
Human Subjects Committee, and each participant provided written consent prior to participation 
in the study.  
  Non-smoking participants age 20-45 with BMI of 27-35 (overweight or class 1 obesity) 
were recruited from two university campuses and from the wider community. Participants were 
instructed to adhere to their usual level of activity during the study period, and information on 
any supplements or medications taken by participants was obtained. Exclusion criteria included 
self-reported hypertension, dyslipidemia, kidney disease, diabetes, heart disease, and metabolic 
disease. Smokers were also excluded. Participants were advised to take no supplements for at 
least one week prior to the study and to avoid anti-inflammatory drugs. Participants were also 
screened for medications which could affect blood glucose, lipids or inflammation and excluded 
if any of these were identified. 
 Recruitment methods included electronic announcements, print flyers, and 
communication with local doctors’ offices, gyms, clubs and community organizations. The goal 
for recruitment was 15 men and 15 women.  Nine men (Age: 34.2 years ± 9.8; BMI: 29.6 kg/m
2
 ± 
2.7) and 10 women (Age: 28.6 years ± 5.5 years; BMI: 31.3 kg/m
2
 ± 2.9) were recruited. One 
female participant was excluded due to extremely high CRP, lipid, and CML measurements. 
Thus, 18 participants (9 males, 9 females) were included in the study. 
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Anthropometric, Biochemical Measurements and Study Protocol  
  Using a cross-over study design, all study participants consumed both study diets. Diet A 
was a low-fat, high AGE diet (LFHA).  Diet B was a high fat, high AGE diet (HFHA). On day 
one of the study, participants reported to the lab for anthropometric measurements. A portable 
stadiometer was used to measure height to the nearest one-quarter inch, and a beam scale was used 
to measure weight to the nearest 0.5 pound. Height and weight measurements were converted to 
centimeters and kilograms for reporting, and body mass index (BMI) was calculated (kg/m
2
). Waist 
circumference was measured with a non-stretch tape measure to the nearest 0.5 cm at the narrowest 
part between the lower costal (10
th
) rib border and iliac crest, using the navel as a marker. 
Percentage body fat was measured using bioelectrical impedance analysis (BIA) (Tanita electronic 
scale). Anthropometric measurements were taken again immediately prior to the second dietary 
intervention period by the same personnel.  
Five blood draws were conducted during each phase of the study. The first blood draw 
was done at baseline during the first trip to the lab with follow-up blood draws to include a 1 
hour, 2 hour and 3 hour post-prandial draws after consumption of the first test breakfast meal. 
After completion of the 3 hour post-prandial blood draw, participants consumed lunch. They 
consumed an afternoon snack, dinner and a bedtime final snack over the course of the remainder 
of the day.  Participants were allowed to come and go during each study day so long as they were 
on-time for blood draws.  They returned to the lab the next morning for another fasting draw.  
 After a two week wash-out period, participants returned to campus for the same 
procedure using the alternate study diet not yet consumed.  Anthropometric measurements 
were done immediately prior to the second dietary intervention period by the same 
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personnel. The same protocol was used for both dietary interventions. Each blood draw was be 
performed by a trained nurse or certified phlebotomist. The order of meals was switched at 
random for test groups beginning the trial so that an almost equal number of subjects completed 
the low-fat diet first (n=10) compared to those consuming the high fat diet first (n=8).    
Diet Intervention 
Participants received two isocaloric study diets: one containing 20% of calories from fat, 
the other with 41% of calories from fat. The fatty acid distribution of both diets was 1:2:1 
(MUFA:PUFA:saturated fat). High AGE cooking methods were used for each: broiling, roasting, 
baking, and frying. See Table 6.1.  
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Table 6.1. Macronutrient and AGE Content of Study Diets:  
Low-Fat, High AGE and High Fat, High-AGE Diet  
Meal Low-Fat Diet High Fat Diet 
Breakfast 
 
 
 
 
 
 
 
 
30 g Rice Krispies cereal [600]* 
250 ml Fat free milk [4] 
25 g (1 slice) whole wheat toast [21]  
w/2.5 g Smart Balance [156] 
90 g smoked deli ham [2114] 
85 g banana [8] 
120 ml 100% apple juice [3] 
Total AGE Meal: [2906] 
30 g Life cereal [394] 
250 ml Whole milk [12] 
25 g (1 slice) whole wheat toast [21] 
 w/5 g Smart Balance [311] 
Bacon, microwaved (20 g) [1805] 
85 g banana [8] 
120 ml 100% apple juice [3] 
Total AGE Meal: [2554] 
Lunch 
 
 
 
 
 
 
 
 
Toasted cheese sandwich: 
25 g x 2 whole wheat bread [42] 
30 g reduced fat cheddar cheese [737] 
2.5 g Smart Balance [156] 
50 g carrot sticks [5] 
240 ml chicken noodle soup [4] 
100 g baked apples with 15 ml honey [46] 
250 ml Coke [7] 
Total AGE Meal: [997] 
Toasted cheese sandwich: 
25 g x 2 whole wheat bread  [42] 
30 g regular cheddar cheese [1657] 
5 g Smart Balance [311] 
50 g carrot sticks [5] 
240 ml chicken noodle soup [4] 
100 g apples-no skin [13] 
250 ml diet Coke [3] 
Total AGE Meal: [2035] 
Dinner 
 
 
 
 
 
 
 
 
 
 
90 g broiled chicken breast [5245] 
100 g Grilled California veggies (broccoli, carrots, 
cauliflower) [226] 
(1.25 tsp corn oil) [150] 
100g roasted potatoes [218] 
35 g whole grain roll [29] 
2.5 g Smart Balance [156] 
60 g Frozen fruit bar [11] 
120 ml orange juice [7] 
360 ml Diet Coke (12 oz can) [4] 
Total AGE Meal: [6046] 
 90 g pan fried chicken breast [4444] 
100 g Grilled California veggies (broccoli, 
carrots, cauliflower) [226] 
(1.25 tsp corn oil) [150] 
50 g fried potatoes [347] 
35 g whole grain roll [29] 
w/5 g Smart Balance [311] 
60 g frozen fruit bar [11] 
360 ml Diet Coke (12 oz can) [4] 
 
Total AGE Meal: [5522] 
Snack 1 
 
 
 
30 g Roasted cashews (1 oz) [2942] 
250 ml fat-free milk [4] 
With 1 Tbsp syrup (chocolate or strawberry) 
Total AGE Snack: [2946] 
30 g Roasted Almonds (1 oz) [1995] 
250 ml whole milk [12] 
 
Total AGE Snack: [2007] 
Snack 2 20 g cocktail peanuts [1667] 
30 g Snyder’s pretzel minis [537] 
120 ml apple juice [3] 
Total AGE Snack: [2207] 
28 g cocktail peanuts [2333] 
30 g goldfish [653] 
 
Total AGE Snack: [2986] 
Total AGE 
(kU) 
2906+997+6046+2946+2207=15,102 KU (1.51 x 107) 2554+2035+5522+2007+2985=15,098 KU 
(1.51 x 107) 
Total 
Calories 
2249 2246 
% Fat 20 % (50g)  
(0.7:1:0.6 SF:MUFA:PUFA) 
41 % (104g) 
(0.9:1:0.5 SF:MUFA:PUFA) 
Protein 108 g (19%) 103 g (18%) 
Carb 356 g (62%) 235 g (41%) 
*Numbers in [brackets] represent the calculated AGE value of the food item from tables 
in the article by Uribarri et. al. 2010.  
 
Breakfast and lunch were consumed in the laboratory. Dinner, afternoon and bedtime 
snacks were consumed in the laboratory or boxed and given to the participant to be consumed at 
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home according to participant need.  Dietary macronutrient content was calculated initially using 
Nutritionist Pro, then confirmed by proximate analysis of the diet by an independent laboratory 
(Pope Labs). Analysis of the diet sample is shown in Table 6.2.  Participants were allowed to eat 
only the study foods during each one day intervention period. 
Table 6.2: Comparison of Calculated Macronutrient Values for Test Diets and 
Experimentally Determined Values. 
 
Biochemical and Food AGE Analysis 
 Blood samples were immediately put on ice, allowed to sit for 10-15 minutes to facilitate 
clotting, and centrifuged at 1200 rpm for 15 minutes. Sera were separated, aliquoted and stored at 
-80
o
C. Sera were analyzed for glucose, triacylglycerol (TG), total cholesterol (TC), and high 
density lipoprotein (HDL) using commercially available kits (StanBio, Boerne, TX).  HMW 
adiponectin was measured using enzyme linked immunoassay kits (ELISA) (Alpco, Salem, NH).  
 Diet A (LF HA): 3.07 kg Diet B (HF HA): 3.37 kg 
Category Pope Calculated Pope Calculated 
Fat 53.7 g (24%) 50 g (20%) 78.2 g (36%) 104 g (41%) 
Protein 0.52% N 
99.7 g (20%) 
108 (19%) 0.48% N 
101.1 g (21%) 
103 g (18%) 
Carbohydrate 302g (60%) 356 g (62%) 213 g (44 %) 235 g (41%) 
Calories 2018 kcals 2249 kcals 1956 kcals 2246 kcals 
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CML, CRP, and sRAGE  were also measured using ELISA (Microcoat, Bernried, Germany; 
Alpco, Salem, NH; Biovendor, Karasek, Czech Republic).  
 Food samples were prepared using defined techniques (Goldberg 2004), then pureed, 
combined, weighed, and frozen. One-hundred gram samples from each diet were retained and 
sent for analysis of macronutrient content (Pope Labs). In our laboratory, food samples were 
weighed, dissolved in PBS and quantified after pre-digestion using proteinase K (Roche 
Laboratories) using CML ELISA kits (Bernried, Germany). Measured dietary AGEs values were 
different from the calculated values. AGE content was similar between diets, with the low-fat diet 
being somewhat higher in AGEs than the high-fat diet. (Table 6.3) 
Table 6.3: Comparison of Measured AGEs to Calculated AGEs in Test Diets 
 Low-Fat Diet High-Fat Diet Low-Fat 
Breakfast 
High Fat 
Breakfast 
Calculated AGE 15, 102 KU 15, 098 KU 2960 KU 2554 KU 
Measured AGE 
Trial 1 
16.9 mg 14.3 mg 5.1 mg (acid 
treated) 
4.2 mg (acid 
treated) 
Measured AGE 
Trial 2 
19.7 mg 16.2 mg 7.4 mg 
(proteinase K 
treated) 
9.2 mg 
(proteinase K 
treated) 
 
Statistical Analyses 
Potential numerical outliers were identified using box plots and 1.5 times the Q1 to Q3 
interquartile range. Data were analyzed with and without outlier data for comparison. Pearson’s 
correlations were performed for all sera and anthropometric parameters. Paired t-tests were used 
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to compare data from the LFHA and HFHA interventions. In addition ANOVA was used to 
compare variables based on weight class, sex, presence or absence of hyperlipidemia, and 
presence or absence of high levels of inflammation. SPSS version 19.0 for Windows was used to 
perform all statistical analyses including descriptive statistics, analysis of data for normality, and 
correlations. 
RESULTS 
 Participants tolerated both the HFHA and LFHA study diets well and ate all of the study 
foods in most cases except one participant was unable to finish her bacon, consuming just 50%.  
One participant reported indigestion, probably due to consumption of diet cola, and another 
participant reported allergic symptoms following consumption of cashew nuts. Otherwise, both 
study diets were well tolerated.  
There were no changes in weight, BMI or percent body fat over the course of the study. 
Men and women were not different with regard to any study variable with the exception of 
percentage body fat. As expected, men had lower percentage body fat (27.4% ± 4.4 compared to 
41.5% ± 4.1 for women; p=0.0001).  Data for males and females were grouped together for 
further analysis. Histograms and box plots were checked to evaluate normality of the samples and 
to check for outliers. Because the sample size was small, data that exceeded 1.5 times the Q1 to 
Q3 interquartile range was not automatically excluded from analysis. Instead only one 
participant’s data was excluded for a single indicator: sRAGE.  It was determined that because 
serum values were 10 times the mean for the other participants, this was a likely true outlier. This 
participant’s sRAGE data was excluded. 
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Although participants were screened for dyslipidemia, half of the participants had 
elevated total cholesterol or triglycerides of which they were unaware. Thus, t-tests were done to 
determine if biochemical or anthropometric data varied based on presence or absence of elevated 
lipids. Significant differences were found only with regard to blood lipids and CRP between 
participants with and without abnormal blood lipids. 
Among overweight (n=10) and obese participants (n=8), there were significant 
differences in change in HMW adiponectin following consumption of the LFHA diet 
(Overweight: -0.6±0.3; Class 1 Obesity: 0.5±0.6; p=0.02) and in CRP (Overweight: 0.01±0.7; 
Class 1 Obesity: -0.06±0.4; p=0.02). All other biochemical values did not differ between groups. 
Participants were stratified based on level of CRP: low, medium, high. Percentage fat, 
HDL and glucose were different among these groups. Other indicators approached but did not 
reach significance. 
CML levels following consumption of the LFHA breakfast meal rose from a fasting 
mean of 610 ng/ml ± 205 to a peak of 716 ± 471 at 2 hours post-prandial (Table 5), then 
decreased to 549 ± 179 at fasting the next day (p=0.12). The average decrease in CML from 
baseline to fasting the next day was 62 ng/ml ± 157 (p=0.12). 
By comparison, following consumption of the HFHA breakfast meal, CML levels rose 
from an average of 523 ng/ml ± 178 to a peak of 642 ± 210 at 3 hours post-prandial (p=0.01), 
then increased (compared to baseline fasting) to 582 ± 232 (p=0.15) the next day. The average 
increase in CML from baseline to fasting the next day was 54 ± 161 (p=0.15). (Table 4) The 
differences in change in CML from baseline to fasting the next day for the two study diets 
approached, but did not reach significance (p=0.08). However, the trend was for LFHA, which 
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was slightly higher in measured AGE, to show a decrease in CML, whereas the HFHA diet, 
which was similar but slightly lower in AGE to demonstrate an increase in CML.  Using a paired 
t-test, area under the curve (AUC) for CML at 0, 1, 2 and 3 hours was found not to differ 
significantly between the two study diets (LFHA: 1932 ± 916; HFHA: 1727 ± 441). In fact, the 
AUC for CML for the two study diets was correlated significantly (R=0.54, p=0.02). 
The raw data demonstrated great variability from person to person in patterns of change 
in CML over time. Seven participants fed the LFHA diet showed a slight decrease in CML post-
prandially following ingestion. Eight showed a slight increase and three a large increase. Only 
one participant fed the HFHA diet showed a slight decrease in CML post-prandially following 
ingestion of the diet with seven participants having a moderate increase and 10 a large increase.  
sRAGE levels following consumption of both the LFHA and HFHA breakfast meals 
decreased significantly from baseline to 1 to 2 to 3 hours post-prandially (p<0.01), then rose the 
next day, though not-significantly. Mean baseline sRAGE prior to the LFHA diet was 545 pg/ml 
± 181 rising to 587 ± 294 (p=0.32) the next day. Mean baseline sRAGE prior to the HFHA diet 
was 534 ± 217 rising to 554 ± 182 the next day (p=0.22). (Table 4) AUC for sRAGE at 0, 1, 2 
and 3 hours did not different significantly between LFHA and HFHA diets. 
Other biochemical parameters changed little from baseline to fasting the next day; 
however, total cholesterol decreased significantly for participants consuming the HFHA diet 
(Baseline: 220 mg/dl ± 46; Post: 209 ±41; p=0.03).  
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Table 6.4. Selected Biochemical Values Grouped According to LFHA and HFHA Diet. 
LFHA Diet HFHA Diet 
 Value Change  Value Change 
CML 0 hr 
(ng/ml) 
610±20
5  
 CML 0 hr 
(ng/ml) 
523±178  
CML 1 hr 615±28
0 
 CML 1 hr 577±176  
CML 2hr 716±47
1 
-
106±415(p=0.3) 
CML 2hr 567±167  
CML 3hr 590±36
9 
 CML 3 hr 642±210 -
114±201(p=0.01)
* 
CML Post 549±17
9 
62±157 (p=0.12) CML Post 582±232 -54±161(p=0.15) 
sRAGE 0hr 
(pg/ml) 
545±18
1 
 sRAGE 0hr 
(pg/ml) 
534±217  
sRAGE 1hr 529±19
9 
 sRAGE 1hr 487±183  
sRAGE 2hr 486±20
7 
 sRAGE 2hr 482±165  
sRAGE 3hr 466±18
6 
97±24 (p=0.01)* sRAGE 3hr 466±176 87±21(p=0.01)* 
sRAGE Post 587±29
4 
79±97 (p=0.32) sRAGE Post 554±182 70±87 (p=0.22) 
HMW Adipo 0 hr 
(µg/ml) 
1.8±0.4  HMW Adipo 0 
hr 
(µg/ml) 
1.8±0.4  
HMW Adipo Post 1.6±0.4  HMW Adipo 
Post 
1.5±0.4  
CRP 0 hr (µg/ml) 1.7±0.4  CRP 0 hr 
(µg/ml) 
1.6±0.4  
CRP Post 1.5±0.4  CRP Post 1.4±0.3  
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DISCUSSION 
 This study is the first to compare consumption of a low-fat and high fat diet, each high in 
AGEs, on serum AGE, sRAGE and indicators of inflammation. While our study was limited by 
several factors, including small sample size, the presence of many participants with 
hyperlipidemia or dyslipidemia despite screening to identify healthy participants, and the short-
term nature of the study, its findings are important in a few ways. 
 Even though both diets were calculated to be the same in AGE and used almost the same 
foods with fruit juices added to the low-fat diet in order to compensate for decreased calories due 
to less fat, the measured content of the LFHA diet appeared to be about 15% higher in AGE than 
the high fat diet. However, whereas consumption of the LFHA diet was associated with a non-
significant decrease in serum CML with no rise in CRP or reduction in adiponectin, the HFHA 
diet was associated with a rise in serum CML but also with no rise in CRP or reduction in 
adiponectin.  
 These findings suggests that dietary AGE may be less significant than other factors in the 
diet such as phytochemicals, dietary fat, or other unidentified factors, which may inhibit AGEs or 
affect other oxidative processes. Whereas several studies have found negative physiological 
effects of single test meals rich in AGE, ours found no such effect. CRP and adiponectin were 
very stable in the presence of both diets (Koschinsky 1997, Diamanti Kandarakis 2006, Uribarri 
2007, Stirban 2006). It is not clear why, with healthful fats included in both test diets, very 
similar micronutrient profiles, and almost identical foods being purchased whenever possible, 
there would be a decrease in CML in the presence of the LFHA diet and a rise in CML after 
consumption of the HFHA diet. This finding suggests that serum CML really is not very 
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significantly influenced by diet in healthy adults at all given such low absorption, so long as these 
adults do not have diabetes. In addition, sRAGE in this study did not appear to be a highly useful 
indicator of metabolic risk. CRP appears to be more sensitive, more stable, and less subject to 
dietary influences.  This adds credence to the finding of Semba et. al. in 2012 in which using 
dietary records to estimate AGE intake did not correlate with serum AGE levels. In this study, 
intake of foods thought to be high in AGEs also did not correlate with serum CML.  
 This study by no means answers any questions in AGE research. It only provides one 
more data point to aid in answering the question: are heat-treated foods in the presence of 
balanced diet, harmful?   Based on these results, our answer at this time would have to be that in 
the short term, they are not.  
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APPENDIX C 
 
Biochemical Analysis Procedures 
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Glucose Procedure: 
 
Thaw Samples: 
1. Begin thawing samples. 
2. Turn on water bath. 
Aliquot into Smaller Samples: 
3. Aliquot 200 µl from thawed samples into microcentrifuge tubes. 
4. Set up template for Wells Plate. 
5. Label test tubes. 
Prepare standards according to the following dilution: 
1. S25: 12.5 µl standard; 37.5 µl DI water 
2. S50: 25 µl standard; 25 µl DI water 
3. S100: 50 µl standard 
Transfer to Test Tubes: 
1. Pipette 1 ml of reagent into each test tube. 
2. Add 10 µl of DI water to blanks. 
Note time: 
3. Add 10 µl of standard to appropriate tubes 
4. Add 10 µl of sample to appropriate tubes. 
5. Vortex each test tube. 
Incubate: 
Put test tube racks in water bath at 37 degrees C for 5 minutes 
Transfer to Wells Plate: 
Begin transferring 300 µl from each test tube to the appropriate well on the Wells Plate. 
Note time: Read plate by 60 minutes from the time you begin putting samples and standards 
into test tubes. Read at 500 nm.  
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Triglyceride Procedure: 
 
Thaw Samples: 
1. Begin thawing samples. 
2. Turn on water bath. 
Aliquot into Smaller Samples: 
1. Aliquot 200 µl from thawed samples into microcentrifuge tubes. 
2. Set up template for Wells Plate. 
3. Label test tubes. 
Prepare standards according to the following dilution: 
1. S50: 12.5 µl standard; 37.5 µl DI water 
2. S100: 25 µl standard; 25 µl DI water 
3. S200: 50 µl standard 
Prepare activated reagent: 
1. Add 50 µl of activator to every 5 ml of regent. (i.e. For 150 ml of reagent, add 1.5 ml 
of activator). 
Transfer to Test Tubes: 
1. Pipette 1 ml of activated reagent into each test tube. 
2. Add 10 µl of DI water to blanks. 
Note time: 
1. Add 10 µl of standard to appropriate tubes 
2. Add 10 µl of sample to appropriate tubes. 
3. Vortex each test tube. 
Incubate: 
Put test tube racks in water bath at 37 degrees C for 5 minutes 
Transfer to Wells Plate: 
Begin transferring 300ml from each test tube to the appropriate well on the Wells Plate. 
Note time: Read plate by 60 minutes from the time you begin putting samples and standards 
into test tubes. Read at 500 nm.  
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Cholesterol Procedure: 
 
Thaw Samples: 
1. Begin thawing samples. 
2. Turn on water bath. 
Aliquot into Smaller Samples: 
1. Aliquot 200 µl from thawed samples into microcentrifuge tubes. 
2. Set up template for Wells Plate. 
3. Label test tubes. 
Prepare standards according to the following dilution: 
1. S50: 12.5 µl standard; 37.5 µl DI water 
2. S100: 25 µl standard; 25 µl DI water 
3. S200: 50 µl standard 
Transfer to Test Tubes: 
1. Pipette 1 ml of reagent into each test tube. 
2. Add 10 µl of DI water to blanks. 
3. Note time: 
4. Add 10 µl of standard to appropriate tubes 
5. Add 10 µl of sample to appropriate tubes. 
6. Vortex each test tube. 
Incubate: 
Put test tube racks in water bath at 37 degrees C for 5 minutes 
Transfer to Wells Plate: 
Begin transferring 300 µl from each test tube to the appropriate well on the Wells Plate. 
Note time: Read plate by 60 minutes from the time you begin putting samples and standards 
into test tubes. Read at 500 nm.  
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HDL Cholesterol Procedure: 
Thaw Samples: 
1. Begin thawing samples. 
2. Turn on water bath. 
 
HDL Separation: 
1. Using a microcentrifuge tube, pipette 200 µl of serum or plasma into the tube.  
2. Add 20 µl of HDL precipitating reagent 
3. Vortex well and allow to stand 5 minutes 
4. Centrifuge for 10 minutes at high speed (10 x g). 
 
Prepare standards according to the following dilution: 
S25: 50 µl standard; 50 µl DI water 
S50: 50 µl standard 
S100: 25 µl of TChol standard, 25 µl of DI water 
 
Transfer to Test Tubes: 
1. Pipette 1 ml of reagent into each test tube. 
2. Add 25 µl of DI water to blanks. 
Note time: 
3. Add 25 µl of standard to appropriate tubes 
4. Add 25 µl of clear supernatant from each sample to appropriate tubes. 
5. Vortex each test tube. 
 
Incubate: 
Put test tube racks in water bath at 37 degrees C for 5 minutes 
 
Transfer to Wells Plate: 
1. Begin transferring 300 µl from each test tube to the appropriate well on the Wells 
Plate. 
 
Note time: Read plate by 60 minutes from the time you begin putting samples and standards 
into test tubes. Read at 500 nm.  
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HMW Adiponectin Procedure: (Alpco) 
 
Reagents: 
Bring reagents to room temperature. 
 
Protease II: (stable for 2 days at 2-10 degrees C; stable for the life of the kit @ -20C) 
Reconstitute Protease II:  
 Add 10 ml of Protease buffer to the Protease II vial. 
 Dissolve completely at room temperature for 15-30 minutes. 
 
Samples: (stable at 2-10 degrees C for 2 days) 
 Bring to room temperature. 
 Aliquot samples. 
 Label microcentrifuge tubes for pretreated samples AND for diluted samples. 
 Add 100 mcl of Protease II to 10 mcl of each sample. 
 Incubate at 37 degrees C for 20 minutes. 
 Immediately add 400 mcl of sample pretreatment buffer. 
 Vortex. 
 Dilute pretreated samples: add 10 mcl of the pretreated sample to 1 ml of Dilution Buffer. 
 Vortex. (DILUTED SAMPLES MUST BE USED WITHIN 2 HRS OF DILUTION.) 
 
Wash Buffer: (Stable at 2-10 degrees C for life of kit) 
 Dilute wash buffer concentrate with 900 ml of distilled water.  
 
Low, High and Serum Controls: (can be stored at -20 degrees C) 
Reconstitute Controls: 
 Add 1 ml DI water to each vial. 
 Replace the rubber stopper and cap. 
 Gently swirl each vial and let stand for 10 minutes prior to use. 
 The contents should be in solution with NO VISIBLE PARTICULATE matter. 
 
Standards: 
 Make 8 standards JUST PRIOR TO LOADING PLATE 
Standard # Calibrator Dilution Buffer Final Concn 
1 10 mcl 1000 mcl 4.8 ng/ml 
2 150 mcl Std1 150 2.4 
3 150 mcl Std2 150  1.2 
4 150 mcl Std3 150 0.6 
5 150 mcl Std4 150 0.3 
6 150 mcl Std5 150 0.15 
7 150 mcl Std 6 150 0.075 
8 0 150 mcl 0 
 
Substrate: (Use immediately after reconstitution and waste any excess.) 
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Just prior to use: add 6 ml Substrate Buffer to the Substrate vial.  
 
Assay: 
First Incubation: 
1. Label/plan your adiponectin template. 
2. Add 50 mcl of each standard (8 PLUS HC, LC AND SC) and each sample into the 
appropriate wells.  
3. Cover and incubate at room temperature for 1 hour. 
First Wash 
1. Decant the plate. Strike against towels. 
2. Wash with 350-400 mcl WB per well using squeeze bottle or automated plate washer. 
3. Decant the plate. Strike against towels. 
4. Wash two more times (3 washes). 
Second Incubation: 
1. Add 50 mcl of biotin labeled monoclonal antibody to each well.  
2. Cover with a plate sealer and incubate for 1 hour at room temperature.  
Second Wash: 
Repeat first wash procedure. 
Third Incubation: 
1. Add 50 mcl of enzyme labeled streptavidin.  
2. Cover with a plate sealer and incubate for 30 minutes at room temperature.  
Third Wash: 
Repeat first wash procedure: 
Fourth Incubation: 
1. Add 50 mcl substrate solution to each well.  
2. Protect the plate from light and incubate for 10 minutes at room temperature. 
Stop: 
1. Add 50 mcl stop reagent to each well. 
2. Read at 492 nm 10-30 minutes after the addition of the stop reagent.  
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CML ELISA Assay 
Prepare Working Solutions: 
Wash buffer: 
 Add 20 ml wash buffer (10x) to 180 ml DI water.  
 Store at 2-8 degrees for one day only 
 
Guidelines: 
1. Bring all working solutions to 15-25 degrees C. 
2. Do NOT aliquot standard, antibodies or conjugate. 
3. Centrifuge standard and conjugate briefly at 6000 rpm x 2 minutes before use. Mix carefully. 
Do NOT vortex. Take only the clear supernatant. 
4. Use plastics, not glassware. 
 
 
Pre-treat samples: 
1. Incubate in a 0.5 ml microcentrifuge tube: (22 x dilution) 
 100 µl wash buffer 
 5 µl sample serum 
 5 µl proteinase K. 
2. Incubate for 2 hours at 37 degrees C (waterbath).  
3. Inactivate proteinase K at 80 degrees C for 10 minutes (time starts when 80 degrees reached) 
using thermoblock. 
4. Cool sample to room temp. 
Begin Assay: 
Add Bi-BSA-AGE: (have 250 µl of BSA-AGE) 
1. Add 70 µl Bi-BSA-AGE to 14 ml assay buffer solution.  
2. Pipet 100 µl Bi-BSA-AGE solution in all wells (except A1 and A2). 
3. Cover with the adhesive foil cover. 
4. Incubate for 1 hour at constant shaking at 15-25 degrees C. 
Wash: 
1. Wash 3 times with 300 µl wash buffer. 
130 
 
2. Remove buffer by aspirating or tapping out solution, especially at last step. 
Add samples and standards: (have 40 µl conjugate) 
1. Add 10 µl MAB-CML-HRP conjugate to 14.5 ml assay buffer.  
2. Add 50 µl standards, positive controls and diluted samples to wells. 
3. Immediately add 50 µl MAB-CML-HRP conjugate in wells except A1 and A2 
4. Cover with an adhesive foil. 
5. Incubate for 1 hour with constant shaking at 15-25 degrees C. 
Wash: 
1. Wash 3 times with 300 µl wash buffer. 
2. Remove buffer by aspirating or tapping out solution, especially at last step. 
Add ABTS solution: 
1. Add 100 µl ABTS solution to all wells. 
2. Cover with an adhesive foil. 
3. Incubate for 30 minutes with constant shaking at 600 rpm at 15-25 degrees C. 
Measure: 
1. Measure the OD of each well at 405 nm, reference 492 nm. 
2. If reading for standard 0 ng/ml is <1 E, prolong incubation to 45-60 minutes. 
3. Use 4 parameter fit method to calculate curve. 
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Biovendor sRAGE ELISA Assay 
Prepare Working Solutions: 
Bring all reagents to room temp.  
Wash buffer: 
 Add 100 ml wash buffer (10x) to 900 ml DI water.  
 Store at 2-8 degrees for up to one month. 
 
Guidelines: 
1. Bring all working solutions to 15-25 degrees C. 
2. Use standard immediately or store at -20 degrees C for up to 3 months. Avoid freezing and 
thawing repeatedly. Do NOT store diluted standard solutions. 
3. Use plastics or very clean glassware. 
 
 
Samples: 
1. Dilute samples 3x with dilution buffer just prior to assay: 100 µl of sample per 200 µl dilution 
buffer. Vortex to mix, but do not allow to foam. Do not store diluted samples.  Samples should be 
thawed just prior to assay. Avoid repeated freezing and thawing. Avoid using hemolyzed or 
lipemic samples. 
 
Standards and Controls: 
 Reconstitute the lyophilized master standard with dilution buffer just before assaying. Let 
it dissolve for 15 minutes with occasional gentle shaking (do not allow to foam). The 
stock solution is 3200 pg/ml. 
 Prepare standards: 
Volume of Standard Dilution Buffer Concentration 
Stock - 3200 pg/ml 
250 µl of stock 250 µl 1600 pg/ml 
250 µl of 1600 pg/ml 250 µl 800 pg/ml 
250 µl of 800 pg/ml 250 µl 400 pg/ml 
250 µl of 400 pg/ml 250 µl 200 pg/ml 
250 µl of 200 pg/ml 250 µl 100 pg/ml 
250 µl of 100 pg/ml 250 µl 50 pg/ml 
 
 Refer to the CofA for the current volume of dilution buffer needed to reconstitute the 
quality controls. 
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 Reconstitute each control just prior to assay. Allow to dissolve for 15 minutes with 
occasional gentle shaking (not to foam). Use them AS IS. DO NOT DILUTE. 
Begin Assay: 
5. Add 100 µl of Standards, Quality Controls, Dilution Buffer (blank) and diluted samples 
in duplicate to each well.  
6. Cover and incubate at room temp (25 degrees C) x 2 hours at 300 rpm on orbital plate 
shaker. 
7. Wash x5 with wash solution (350 µl per well) After final wash, invert and tap plate 
strongly against a paper towel. 
8. Add 100 µl of biotin labeled antibody to each well. 
9. Incubate at room temp (25 degrees C) x 1 hour at 300 rpm on orbital plate shaker. 
10. Wash x5 with wash solution (350 µl per well) After final wash, invert and tap plate 
strongly against a paper towel. 
11. Add 100 µl of streptavidin HRP conjugate into each well. 
12.  Incubate at room temp (25 degrees C) x 30 minutes at 300 rpm on orbital plate shaker. 
13. Wash x5 with wash solution (350 µl per well) After final wash, invert and tap plate 
strongly against a paper towel. 
14. Add 100 µl of substrate solution into each well. Avoid exposing to sunlight. Cover the 
plate with foil. 
15. Incubate the plate x 10 minutes at room temperature. The incubation can be extended up 
to 20 if the temp is below 20 degrees. Do not shake during incubation. 
16. Stop the color development by adding 100 µl of stop solution. 
17. Determine the absorbance by measuring at 450 nm with reference wavelength set to 630 
nm. 
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WANTED: Participants 
Are you . . . ? 
 Age 20-45? 
 Overweight? 
 Healthy? 
We need men and women to participate in a study about the effect of diet on AGE (advanced 
glycation end products) and inflammation.  
You will receive: 
 Free food x 2 days. 
 $5 compensation at the end of the study. 
 A FREE three-hour seminar on weight management. 
  
(You must be ages 20-45, BMI 27-35, and free of high blood pressure, diabetes, heart disease, 
cancer, & kidney disease):   
To find out if you qualify to participate:  
Call or e-mail Kathleen Davis: 
KDavis10@twu.edu; 940-395-8577 
This is for research purposes only and is VOLUNTARY. 
There is a potential risk of loss of confidentiality in all email, downloading, and Internet 
transactions 
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Portal Announcement/Facebook Announcement: 
 
WANTED: Participants!! Are you . . . ? 
 Age 20-45? 
 Overweight? 
 Healthy? 
We need men and women to participate in a study about the effect of diet on AGE (advanced 
glycation end products) and inflammation.  You will receive: free food x 2 days, $5 compensation 
at the end of the study, and A FREE three-hour seminar on weight management. (You must be 
ages 20-45, BMI 27-35, and free of high blood pressure, diabetes, heart disease, cancer, & 
kidney disease):   
To find out if you qualify to participate: Call or e-mail Kathleen Davis: KDavis10@twu.edu; 
940-395-8577. This is for research purposes only and is VOLUNTARY. There is a potential risk 
of loss of confidentiality in all email, downloading, and Internet transactions 
 
  
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX E 
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Telephone Recruitment Script for Potential Participants in AGE Feeding Study 
Researcher: 
Thank you for contacting me regarding participating in our study at TWU Nutrition and Food 
Sciences on foods containing advanced glycation end products.  
We are looking for participants who are 20-45 years old, both male and female, who are 
overweight and willing to eat our study foods for two days during this spring (2012).  If you 
would like, I will send you a chart to help you tell if you meet our study criteria. May I please 
have your e-mail address? 
I am sending you a chart to use to determine your BMI. We need people whose BMI’s are 
between 27 and 35. If you would like to participate, send me a note back, and I will schedule a 
time to meet with you to fill out your consent form.  
Thank you again! 
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E-mail Script: 
Thank you for contacting me regarding participating in our study at TWU Nutrition and Food 
Sciences on foods containing advanced glycation end products. We are looking for participants 
who are 20-45 years old, both male and female, who are overweight and willing to eat our study 
foods for two days during this spring (2012). 
Use This Chart to Determine Your BMI: (We are looking for people with a BMI between 27 
and 35.) 
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Source: http://www.nhlbi.nih.gov/guidelines/obesity/bmi_tbl.htm 
The study will require that you come to campus (Old Main Building) for a fasting blood draw on 
a Friday, stay for breakfast and stay for three (3) post meal blood draws, one, two, and three hours 
later. You will then return to campus (the Human Development Building) the same day for lunch, 
dinner and a snack and will come back to campus the next day (Saturday) for another fasting 
blood draw.  You will be allowed to eat only the study foods during that day. Please do not eat 
other foods during the study period.  During the first visit to campus, a researcher of the same sex 
will weigh you, measure your height and measure your waist in a screened area. A certified 
phlebotomist (person taking your blood) or nurse will then draw about 12 tablespoons of your 
blood.  
Two weeks later we will repeat the same schedule. You will come to campus (Old Main 
Building) for a fasting blood draw on a Friday, stay for breakfast and stay for three (3) post meal 
blood draws, one, two, and three hours later. You will then return to campus (the Human 
Development Building) the same day for lunch, dinner and a snack and will come back to campus 
the next day (Saturday) for another fasting blood draw.  You will be allowed to eat only the study 
foods during that day. Please do not eat other foods during the study period. 
141 
 
This study will also require that you keep one five day food diary prior to the study. This study 
will require about 13 hours of time from you during a four week period. 
 
You will receive a diet that is high fat (40 percent fat) during one study day and a diet that is low 
fat (20% fat) another study day.  Each diet will have the same number of calories. Both diets will 
be high in AGEs and will be cooked using high heat cooking methods such as broiling, roasting, 
baking, grilling, and frying. You may eat ONLY the study foods during each one day 
intervention. Let us know if you are still hungry after eating the study foods so that we can 
increase your portions. 
To thank you for your participation, you will receive $5 compensation, and you will be invited to 
participate in a free three-hour seminar on weight management. If you wish to receive the 
newsletter, you will need to provide your mailing or e-mail address. If you would like to receive 
your blood results from the study, you will need to provide your mailing or e-mail address.   
If you would like to participate in the study, please call or e-mail me: 940-395-8577 or 
KDavis10@twu.edu. I will set a time for you to come to campus to meet with me and sign a 
consent form. Then we will be able to answer further questions that you may have. 
Thank you for your time. Please call me (940-395-8577) or respond to this e-mail 
(KDavis10@twu.edu), and we will set up a time to meet with you.  
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Screening Questionnaire 
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SCREENING QUESTIONNAIRE 
ID:         
Consent Obtained:    
Sex: F   M   Age   
Telephone:     Email:        
Do you smoke? Y  N  Have you smoked or used smokeless tobacco in the past 
6 months?   
Are you pregnant? Y N  Are you lactating?Y N  
Weight   Height   BMI   
Medical condition(s) for which you are taking medicine:   
Hypertension  High Cholesterol  Kidney Disease Diabetes   
Lung Disease   Heart Disease   Liver Disease   
Other Conditions For Which you Take Medication       
 
Has a doctor ever told you that you have any of the following diseases? 
High blood pressure   High cholesterol  Heart disease    
Diabetes   Kidney Disease   Metabolic Disease    
Cancer    
______________________________________________________________________________ 
List any medications, drugs, prescription drugs, over the counter drugs, vitamins or food 
supplements you are taking: List amount (mg) and times taken (daily, weekly, etc.) 
Name  Amount (mg) Times Taken (daily, weekly, 
etc.) 
   
   
144 
 
   
   
   
 
Do you have any food allergies? _______N    ________Y What are they?    
             
 
Which race/ethnicity do you identify with? (you may select more than one) 
 White/Caucasian 
 Black/African-American 
 Asian 
 Hispanic 
 Native American 
 Other 
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Food Journal Form 
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Food Journal 
ID: 
Date & 
time 
Food, drink, snack, how 
prepared and amount. Example: 
chicken breast, breaded, fried in 
oil  
Location 
(ex Home, 
car, bar 
restaurant) 
Do not write in this column 
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Data Collection Form 
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Data Collection Form 
Participant #________________________          
Date        (initial draw) 
Diet        
  
 
Date        (Follow-Up Draw) 
Diet        
 
 
 
 
BMI Weight Height Waist Circum. 
    
Action Time 
Blood Drawn Fasting  
Consumed Breakfast  
Blood Drawn 1 Hours after eating  
Blood Drawn 2 Hours after eating  
Blood Drawn 3 Hours after eating  
Action Time 
Blood Drawn Fasting  
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Sample Menus 
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Sample Menus 
 
Meal Low-Fat Diet High Fat Diet 
Breakfast 
 
 
 
 
 
 
 
 
30 g Rice Krispies cereal [600] 
250 ml Fat free milk [4] 
25 g (1 slice) whole wheat toast [21]  
w/2.5 g Smart Balance [156] 
90 g smoked deli ham [2114] 
85 g banana [8] 
120 ml 100% apple juice [3] 
 
Total AGE Meal: [2906] 
30 g Life cereal [394] 
250 ml Whole milk [12] 
25 g (1 slice) whole wheat toast [21] 
 w/5 g Smart Balance [311] 
Bacon, microwaved (20 g) [1805] 
85 g banana [8] 
120 ml 100% apple juice [3] 
 
Total AGE Meal: [2554] 
Lunch 
 
 
 
 
 
 
 
 
Toasted cheese sandwich: 
25 g x 2 whole wheat bread [42] 
30 g reduced fat cheddar cheese [737] 
2.5 g Smart Balance [156] 
50 g carrot sticks [5] 
250 ml chicken noodle soup [4] 
100 g baked apples with 15 ml honey 
[46] 
250 ml Coke [7] 
 
Total AGE Meal: [997] 
Toasted cheese sandwich: 
25 g x 2 whole wheat bread  [42] 
30 g regular cheddar cheese [1657] 
5 g Smart Balance [311] 
50 g carrot sticks [5] 
250 ml chicken noodle soup [4] 
100 g apples-no skin [13] 
250 ml diet Coke [3] 
 
Total AGE Meal: [2035] 
Dinner 
 
 
 
 
 
 
 
 
 
 
90 g broiled chicken breast [5245] 
100 g Grilled California veggies 
(broccoli, carrots, cauliflower) [226] 
(1.25 tsp corn oil) [150] 
100g roasted potatoes [218] 
35 g whole grain roll [29] 
2.5gl Smart Balance [156] 
60 g Frozen fruit bar [11] 
120 ml orange juice [7] 
360 ml Diet Coke (12 oz can) [4] 
Total AGE Meal: [6046] 
 90 g pan fried chicken breast [4444] 
100 g Grilled California veggies 
(broccoli, carrots, cauliflower) [226] 
(1.25 tsp corn oil) [150] 
50 g fried potatoes [347] 
35 g whole grain roll [29] 
w/5 g Smart Balance [311] 
60 g frozen fruit bar [11] 
360 ml Diet Coke (12 oz can) [4] 
 
Total AGE Meal: [5522] 
Snack 1 
 
 
 
30 g Roasted cashews (1 oz) [2942] 
250 ml fat-free milk [4] 
With 1 Tbsp syrup (chocolate or 
strawberry) 
Total AGE Snack: [2946] 
30 g Roasted Almonds (1 oz) [1995] 
250 ml whole milk [12] 
 
Total AGE Snack: [2007] 
Snack 2 20 g cocktail peanuts [1667] 
30 g Snyder’s pretzel minis [537] 
120 ml apple juice [3] 
Total AGE Snack: [2207] 
28 g cocktail peanuts [2333] 
30 g goldfish [653] 
 
Total AGE Snack: [2986] 
Total AGE 
(kU) 
2906+997+6046+2946+2207=15,102 
KU (1.51 x 10
7
) 
2554+2035+5522+2007+2985=15,098 
KU (1.51 x 10
7
) 
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Total 
Calories 
2249 2246 
% Fat 20 % (50g)  
(0.7:1:0.6 SF:MUFA:PUFA) 
41 % (104g) 
(0.9:1:0.5 SF:MUFA:PUFA) 
Protein 108 g (19%) 103 g (18%) 
Carb 356 g (62%) 235 g (41%) 
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Macronutrient Analysis by Independent Lab 
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POPE TESTING LABORATORIES, INC. 
CONSULTING ANALYTICAL CHEMISTS 
Food, Nutritional, Water and Agricultural Analysis 
2220 Hinton Drive          
 Phone: 972-871-2892 
Irving, TX  75061          
  972-871-7188 
pope.labs@yahoo.com         
 Fax: 972-871-7452 
 
March 8, 2012 
 
 
Texas Woman’s University 
 P.O. Box 425888 
 Denton, TX 76204 
  
 Attn: Nutrition & Food Science 
 
Report of Tests on: Food 
 
 
 
     Study Diet A  Study Diet B 
 
 
   Moisture     84.73 %    87.89 % 
 
   Oil (AH)       1.75 %      2.32 % 
 
   Ash        0.68 %      0.50 % 
 
   Nitrogen       0.48 %      0.31 % 
 
   Nitrogen (re-run)      0.52 %      0.48 % 
 
   Carbohydrates       9.84       7.37 
 
   Carbohydrates (w/ Nitrogen re-run) 9.59      6.32 
 
   Calories     67.11         58.04 
 
 
 
Calculated Macronutrient Data Compared to Measured Data 
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 Diet A (LF HA): 3.07 kg Diet B (HF HA): 3.37 kg 
Category Pope Calculated Pope Calculated 
Fat 53.7 g (24%) 50 g (20%) 78.2 g (36%) 104 g (41%) 
Protein 0.52% N 
99.7 g (20%) 
108 (19%) 0.48% N 
101.1 g (21%) 
103 g (18%) 
Carbohydrate 302g (60%) 356 g (62%) 213 g (44 %) 235 g (41%) 
Calories 2018 kcals 2249 kcals 1956 kcals 2246 kcals 
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CML Measurement in Food Procedure 
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CML Measurement in Food 
 
 Prepare study meals. 
 Homogenize the food at room temperature as needed using water to achieve homogenization. 
 Thaw 80 g sample of each diet. 
 Modification: sample was lyophilized, reconstituted to original concentration) 
 Mix 1 ml of each sample with 9 ml 1x PBS. (10 x dilution). 
 
Prepare three sets of samples for each diet (one untreated, one treated with Proteinase K, one 
treated with acid). 
 
Proteinase K Treatment: 
1. Need to know protein concentration of samples: in this case, it is approximately 30 
mg/ml of each sample. 
2. Apply Proteinase K (15.6 mg/ml) to food samples at a concentration of 0.2% (w/w).  
 Weight/weight % = Grams solute/grams solution x 100. 
a. 0.2% = 0.2 mg Prot K protein/100 mg food protein 
 = Food homogenate (non-dilute) contains ~100 g protein/3070 ml or about 30 
mg/ml. 
 10x dilute homogenate contains ~100 g protein/30.7 ml or about 3 mg/ml 
 For 100 mg food protein, you would need 33.3 ml of non-dilute homogenate. 
(100/3) 
 To provide 0.2 mg of protein from Prot K, you need 12.8 µl of proteinase K 
(15.6/1000=0.2/x) 
 
b. Thus, to provide a 0.2% w/w solution, you need 12.8 µl of  prot K, and 33.3 ml – 
12.8 or 33.287 ml of dilute food homogenate.  
 
c. This needs to be scaled down because proteinase K supply is very limited and 
only 50 µl of sample is needed per well. Instead we will use 2 µl Proteinase 
K/5.19 ml dilute food homogenate.      (.0128/33.2 = .002/x)  
 
 (To summarize: 2 µl proteinase K =  31.2 µg protein (0.312 mg) . 5.19 ml  dilute 
food homogenate = 16 mg protein; .312/16 = 2% solution. 
 
Note:  This is the concentration recommended by Dr. Uribarri.  In the CML 
ELISA assay by Microcoat, the amount of proteinase K/serum protein is 
actually 22% w/w. If these concentrations were to be used, then you would need 
1410 µl of prot K per 33.3 ml dilute homogenate, which would amount to 5 µl 
proteinase K per 118 µl dilute food homogenate.   
 
3. Apply 2 µl proteinase K to 5.19 ml food homogenate.  
4. Incubate at 37 degrees C overnight in the water bath. 
5. Deactivate proteinase K at 65 degrees C for 1 hour.  
6. Spin at 1000 rpm x 10 minutes. 
7. Remove 50 µl of supernatant to use on CML assay. 
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Acid treatment: 
1. Take 10x dilute homogenate.  
2. Treat with 6 mm HCl.  C1V1=C2V2 (Start with 8N HCl) 
 8*V1=6
-3
 *2 
 V1 =0.0015  
3. Add 1.5 µl 8 N HCl to 2 ml 10x dilute food homogenate. 
4. Vortex. Allow to stand x 1 hour on orbital mixer. 
5. Neutralize drop by drop using 5 M NaOH 
6. When pH = 7.0, stop. 
7. Centrifuge sample. 
8. Apply 50 µl of supernatant to CML assay. 
 
Untreated sample. 
1. Centrifuge at 1000 rpm x 10 minutes. 
2. Apply 50 µl of supernatant to CML assay. 
  
158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX L 
 
CRP Procedure 
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CRP Procedure: (Alpco) 
Reagents: 
Bring reagents to room temperature and mix well. 
Kit can be used up to 4 times within expiration date. 
Reagents with a volume of less than 100µl should be centrifuged before use.  
 
Wash Buffer: (Stable at 2-8 degrees C for 1 month) 
 Dilute 100 ml wash buffer concentrate with 900 ml of distilled water (10x dilution).  
 
Conjugate: 
Dilute conjugate 100x in 1x wash buffer. (100 µl conjugate + 9900 µl WB).  (Diluted conjugate 
should not be stored.) 
 
Samples: (Must be diluted 1:100-1:500 before performing the assay) 
 Thaw. Then immediately place on ice. 
 Aliquot samples. 
 Label microcentrifuge tubes. 
 Add 10 mcl of sample to 990 µl sample buffer (1:100 dilution). Mix well by vortexing. 
 
Assay: 
4. Label/plan your adiponectin template. 
First Wash 
5. Wash with 250 µl WB per well x 5. 
6. Decant the plate. Strike against towels after final wash. 
First Incubation: 
3. Add 100 µl of standard, sample and control in duplicate into each well. 
4. Cover with a plate sealer and incubate for 1 hour at room temperature on a horizontal 
mixer. 
Second Wash: 
1. Discard contents of wells. 
2. Wash with 250 µl  of WB per well x 5. 
3. Decant the plate. Strike against towels after final wash. 
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Second Incubation: 
3. Add 100 µl of conjugate into each well. 
4. Cover with a plate sealer and incubate for 1 hour at room temperature. 
Third Wash: 
4. Discard contents of wells. 
5. Wash with 250 µl  of WB per well x 5. 
6. Decant the plate. Strike against towels after final wash. 
Third Incubation 
1. Add 100 µl of substrate into each well.  
2. Cover with a plate sealer and incubate for 10-20 minutes at room temperature in the dark.  
Stop: 
3. Add 50 mcl stop reagent to each well. 
4. Read at 450 nm immediately. Use a reference wavelength of 630 nm.  
If the highest standard has an OD that is overflow (S6), read the absorption at 405 nm. 
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CURRICULUM VITAE 
 
Kathleen Davis 
 
Education 
 
Ph.D. To Complete 5/2013     Nutrition, Texas Woman’s University 
M.S.                                    2001        Nutrition, Texas Woman’s University 
B.S.                                    1998             Dietetics, Texas Woman’s University 
B.A. 1995 French, University of North Texas 
 
Dissertation 
 
Dietary AGE, Diet, BMI, and Serum AGE/sRAGE:  Links in a Chain?, May 2013, Victorine 
Imrhan 
 
Professional Certification/Licensure: 
Registered Dietitian, Licensed Dietitian, Board Certified Specialist, Pediatric Nutrition 
 
Employment 
Spring 2013, University of North Texas, Adjunct Instructor: Principles of Nutrition 
 
Fall 2012 to Present, Quality Matters, Quality Matters Course Reviewer 
 
August 2012 to Present, Cook Children’s Medical Center, Outpatient Dietitian 
 
Fall 2007 to Present, Owner Kathleen Davis, MS/RD/LD, Dietitian Sole Proprietorship/Nutrition 
Private Practice 
 
Summer 2009-Fall 2009, Summer 2010-December 2012, Texas Woman’s University, Graduate 
Assistant 
 
Fall 2008-Spring 2009, Texas Woman’s University, Visiting Clinical Instructor 
 
Spring 2005, Spring 2007, Spring 2008, Texas Woman’s University, Adjunct Clinical Instructor 
 
Fall 2002, Tarrant County College, Adjunct Instructor 
 
November 2005-full-time until October 2007; PRN until April 2011, Texas Health Presbyterian 
Hospital Denton, Clinical Dietitian 
 
June 2002-November 2005, Cook Children’s Medical Center, Outpatient Dietitian 
 
April 2001-June 2002, Harris Methodist Hospital, Ft. Worth, Clinical Dietitian 
January 2000-April 2001, Gainesville Memorial Hospital, Director, Dietary Services and Clinical 
Dietitian 
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TEACHING 
 
Courses Taught at TWU 
Developed and/or revised to meet Quality Matters criteria: three on-line courses:   
NFS 3063 Ecology of Food and Nutrition 
NFS 3173 Culture and Food 
NFS 3073 Nutrition for Women in a Global Environment.  
 
Teaching:  
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NFS 3033 Nutrition Throughout the Life Cycle 
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Other Scholarly Teaching, Mentoring and Curricular Achievements 
 Certified Quality Matters Peer Reviewer for on-line courses. 
 Developed guidelines for measuring goal attainment for Global Perspectives criteria for three 
courses in preparation for SACS accreditation. Developed measurable SLOs for 
undergraduate courses. 
 
 
 
SCHOLARSHIP/CREATIVE ACHIEVEMENTS 
 
 
Refereed Publications or Other Creative Achievements 
 
Davis K, Imrhan V. Inclusion of cottonseed oil in a 5 day high fat diet regimen lowers total and 
LDL cholesterol in normo-cholesterolemic, healthy participants. (Published on-line: Nutrients 
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Davis K, Prasad C, Imrhan V. Advanced Glycation End Products, Inflammation, and Chronic 
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Correlates Inversely with Body Mass Index (BMI) and Waist Circumference and Positively 
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Association FNCE 2011.  
 
Davis K, Imrhan V. Effect of Participation in a University Nutrition Course with a Body Image 
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Dietetic Association FNCE 2002. 
 
Invited Speaker: 
Invited Speaker: ―Optimizing Nutrition Education for Pediatric Weight Management‖ Meeting 
presentation at Ft. Worth Association of Nutrition and Dietetics. (November 2012) 
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2004) 
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Texas Dietetic Association Reviewer (2008): Pregnancy and Lactation chapter of the TDA 
Nutrition Care Manual.  
 
Nursing in Pediatrics (2004), publication of Cook Children’s Medical Center. 
Wrote segment on exercise for ―The Three Components of Pediatric Weight Management: How 
to Help Children (and Their Parents) Live Healthier Lives‖.  
 
Quoted in article for Dallas/Ft. Worth Child Magazine: 12/2012: ―When Your Child Wants to be 
a Vegetarian‖. http://www.dfwchild.com/Dallas/showarticle.asp?artid=2007 
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Featured in news story on Fox 4 News (DFW) 9/17/2012: ―Kids Eat Too Much Salt, as Much as 
Adults‖. http://www.myfoxdfw.com/story/19566003/cdc-us-kids-eat-too-much-salt-as-much-as-
adults 
 
Regular blog contributor to wedoitallforkids.com 
 
 PROFESSIONAL SERVICE 
 
 
Service to the Profession 
 
Graduate Club, Texas Woman’s University Nutrition and Food Sciences 
President 
(September 2011 to August 2012) 
 
North Texas Dietetic Association 
Committee Leader: Silent Auction Baskets for TDA 
(Spring 2007) 
 
Service to the Community 
 
Down Syndrome Camp EASE: Eating, Activity and Supported Environment  
(Spring 2012) 
Assisted with development of research method and IRB for proposed camp slated for kick-off in 
Summer 2012. Performed menu analysis for Down Syndrome camp. Worked with chef to edit 
kid-friendly, healthy meals. Developed curriculum to use with kids in the camp.  
 
Lay Teaching Committee Member at First United Methodist Church  
(Spring 2011) 
Provided feedback and support for a theological intern in Christian Education from SMU Perkins 
School of Theology.  
 
North Texas Milk Bank.  
(January 2004-November 2005) 
Member of the Medical Advisory Board. 
 
Denton County Friends of the Family, Denton, TX 
(January-April, 1997, 1998, 1999, 2000, 2001) 
1997 – 1998 Committee Leader; 1999 – 2000 Co-Chair, Speaker, wrote article published in 
Dallas Morning News 
 
DFW HIV/AIDS Nutrition Alliance, Dallas TX 
(January 2000-June 2002) 
Provided free nutrition counseling to HIV positive clients. 
 
